BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 300] [Cited by in F6Publishing: 254] [Article Influence: 100.0] [Reference Citation Analysis]
Number Citing Articles
1 Carvello M, Bellato V, Maroli A, Hart A, Danese S, Warusavitarne J, Spinelli A. A multidisciplinary approach to rectal cancer treatment in ulcerative colitis results in high rate of restorative minimally invasive surgery. J Crohns Colitis 2021:jjab139. [PMID: 34346483 DOI: 10.1093/ecco-jcc/jjab139] [Reference Citation Analysis]
2 Lukin D, Faleck D, Xu R, Zhang Y, Weiss A, Aniwan S, Kadire S, Tran G, Rahal M, Winters A, Chablaney S, Koliani-Pace JL, Meserve J, Campbell JP, Kochhar G, Bohm M, Varma S, Fischer M, Boland B, Singh S, Hirten R, Ungaro R, Lasch K, Shmidt E, Jairath V, Hudesman D, Chang S, Swaminath A, Shen B, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31388-4. [PMID: 33039584 DOI: 10.1016/j.cgh.2020.10.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 Vong C, Martin SW, Deng C, Xie R, Ito K, Su C, Sandborn WJ, Mukherjee A. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. Clin Pharmacol Drug Dev 2021;10:229-40. [PMID: 33513294 DOI: 10.1002/cpdd.899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Murphy B, Kavanagh DO, Winter DC. Modern surgery for ulcerative colitis. Updates Surg 2020;72:325-33. [DOI: 10.1007/s13304-020-00719-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Olaiya B, Renelus BD, Filon M, Saha S. Trends in Morbidity and Mortality Following Colectomy Among Patients with Ulcerative Colitis in the Biologic Era (2002-2013): A Study Using the National Inpatient Sample. Dig Dis Sci 2021;66:2032-41. [PMID: 32676826 DOI: 10.1007/s10620-020-06474-1] [Reference Citation Analysis]
6 Barnes EL, Jiang Y, Kappelman MD, Long MD, Sandler RS, Kinlaw AC, Herfarth HH. Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis. Inflamm Bowel Dis 2020;26:1225-31. [PMID: 31634390 DOI: 10.1093/ibd/izz247] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Goold E, Pearson L, Johnson LM. Can fecal calprotectin serve as a screen for necrotizing enterocolitis in infants? Clin Biochem 2020;84:51-4. [PMID: 32628920 DOI: 10.1016/j.clinbiochem.2020.06.015] [Reference Citation Analysis]
8 Ma X, Xu H, Zhang D. Impact of biological agents and tofacitinib for moderate-to-severe ulcerative colitis on health-related quality of life: a protocol for a network meta-analysis. BMJ Open 2021;11:e055182. [DOI: 10.1136/bmjopen-2021-055182] [Reference Citation Analysis]
9 Wang B, Gong Z, Zhan J, Yang L, Zhou Q, Yuan X. Xianglian Pill Suppresses Inflammation and Protects Intestinal Epithelial Barrier by Promoting Autophagy in DSS Induced Ulcerative Colitis Mice. Front Pharmacol 2020;11:594847. [PMID: 33584273 DOI: 10.3389/fphar.2020.594847] [Reference Citation Analysis]
10 Yalchin M, Baker AM, Graham TA, Hart A. Predicting Colorectal Cancer Occurrence in IBD. Cancers (Basel) 2021;13:2908. [PMID: 34200768 DOI: 10.3390/cancers13122908] [Reference Citation Analysis]
11 Maida M, Morreale GC, Sferrazza S, Sinagra E, Scalisi G, Vitello A, Vettori G, Rossi F, Catarella D, Di Bartolo CE, Schillaci D, Raimondo D, Camilleri S, Orlando A, Macaluso FS. Effectiveness and safety of 1L PEG-ASC preparation for colonoscopy in patients with inflammatory bowel diseases. Dig Liver Dis 2021;53:1171-7. [PMID: 33994129 DOI: 10.1016/j.dld.2021.04.006] [Reference Citation Analysis]
12 Johnson CM, Linzay CD, Dassopoulos T. Maneuvering Clinical Pathways for Ulcerative Colitis. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0716-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Christensen B, Hanauer SB, Gibson PR, Turner JR, Hart J, Rubin DT. Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. J Crohns Colitis 2020;14:1345-53. [PMID: 32267926 DOI: 10.1093/ecco-jcc/jjaa068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
14 Ogata H, Hagiwara T, Kawaberi T, Kobayashi M, Hibi T. Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study. Intest Res 2021;19:419-29. [PMID: 33166442 DOI: 10.5217/ir.2020.00033] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Alhalabi M, Eddin KA, Ali F, Abbas A. SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report. Medicine (Baltimore) 2022;101:e28722. [PMID: 35089243 DOI: 10.1097/MD.0000000000028722] [Reference Citation Analysis]
16 Yang T, Cui X, Tang M, Qi W, Zhu Z, Shi M, Yang L, Pei H, Zhang W, Xie L, Xu Y, Yang Z, Chen L. Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem 2022. [PMID: 35113547 DOI: 10.1021/acs.jmedchem.1c01137] [Reference Citation Analysis]
17 Weissman S, Sinh P, Mehta TI, Thaker RK, Derman A, Heiberger C, Qureshi N, Amrutiya V, Atoot A, Dave M, Tabibian JH. Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation. World J Gastrointest Pathophysiol 2020; 11(5): 104-113 [PMID: 32832194 DOI: 10.4291/wjgp.v11.i5.104] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Patel M, Gulati S, Iqbal F, Hayee B. Rapid development of accurate artificial intelligence scoring for colitis disease activity using applied data science techniques. Endosc Int Open 2022;10:E539-43. [DOI: 10.1055/a-1790-6201] [Reference Citation Analysis]
19 Fleshner P, Melmed GY. Acute Severe Colitis: The Need for Joint Management between Gastroenterologists and Surgeons. Clin Colon Rectal Surg 2022;35:066-71. [DOI: 10.1055/s-0041-1740030] [Reference Citation Analysis]
20 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Lee J, Lemons N, Lorenze A, Chowdhary TS, Zinn Z, Gayam S. Management of cutaneous side effects of inflammatory bowel disease therapy: A dermatologic viewpoint. J Gastroenterol Hepatol 2021. [PMID: 34139789 DOI: 10.1111/jgh.15570] [Reference Citation Analysis]
22 Dohos D, Hanák L, Szakács Z, Kiss S, Párniczky A, Erőss B, Pázmány P, Hegyi P, Sarlós P. Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2021;53:220-33. [PMID: 33249621 DOI: 10.1111/apt.16182] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
23 Xiao BH, Ma XD, Lv JJ, Yang T, Liu XJ, An LY, Qi YX, Lu ML, Duan YQ, Sun DL. Systematic evaluation of the diagnostic approach of inflammatory bowel disease guidelines. Int J Clin Pract 2021;:e14365. [PMID: 34008296 DOI: 10.1111/ijcp.14365] [Reference Citation Analysis]
24 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Weber AT, Shah ND, Sauk J, Limketkai BN. Popular Diet Trends for Inflammatory Bowel Diseases: Claims and Evidence. Curr Treat Options Gastroenterol 2019;17:564-76. [PMID: 31705371 DOI: 10.1007/s11938-019-00248-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
26 Henn MR, O'Brien EJ, Diao L, Feagan BG, Sandborn WJ, Huttenhower C, Wortman JR, McGovern BH, Wang-Weigand S, Lichter DI, Chafee M, Ford CB, Bernardo P, Zhao P, Simmons S, Tomlinson AD, Cook DN, Pomerantz RJ, Misra BK, Auninš JG, Trucksis M. A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis. Gastroenterology 2021;160:115-127.e30. [PMID: 32763240 DOI: 10.1053/j.gastro.2020.07.048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Skupsky J, Sabui S, Hwang M, Nakasaki M, Cahalan MD, Said HM. Biotin Supplementation Ameliorates Murine Colitis by Preventing NF-κB Activation. Cell Mol Gastroenterol Hepatol 2020;9:557-67. [PMID: 31786364 DOI: 10.1016/j.jcmgh.2019.11.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
28 Núñez F P, Quera R, Rubin DT. Endoscopic colorectal cancer surveillance in inflammatory bowel disease: Considerations that we must not forget. World J Gastrointest Endosc 2022; 14(2): 85-95 [DOI: 10.4253/wjge.v14.i2.85] [Reference Citation Analysis]
29 Di Jiang C, Raine T. IBD considerations in spondyloarthritis. Ther Adv Musculoskelet Dis 2020;12:1759720X20939410. [PMID: 32695235 DOI: 10.1177/1759720X20939410] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Ollech JE, Dwadasi S, Rai V, Peleg N, Normatov I, Israel A, Sossenheimer PH, Christensen B, Pekow J, Dalal SR, Sakuraba A, Cohen RD, Rubin DT. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2020;51:637-43. [DOI: 10.1111/apt.15616] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
31 Hong SJ, Katz S. The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management. Therap Adv Gastroenterol 2021;14:17562848211023399. [PMID: 34276809 DOI: 10.1177/17562848211023399] [Reference Citation Analysis]
32 Reznicek E, Arfeen M, Shen B, Ghouri YA. Colorectal Dysplasia and Cancer Surveillance in Ulcerative Colitis. Diseases 2021;9:86. [PMID: 34842672 DOI: 10.3390/diseases9040086] [Reference Citation Analysis]
33 Rodriguez-Palacios A, Basson AR, Cominelli F. Artificial Sweeteners and Whole-Food Science: Could Mice Help Clinicians Make Diet Recommendations for IBD Patients? Gastroenterology 2021;161:8-14. [PMID: 33798527 DOI: 10.1053/j.gastro.2021.03.041] [Reference Citation Analysis]
34 Solitano V, Fiorino G, D'Amico F, Peyrin-Biroulet L, Danese S. Thrombosis in IBD in the Era of JAK Inhibition. Curr Drug Targets 2021;22:126-36. [PMID: 32881668 DOI: 10.2174/1389450121666200902164240] [Reference Citation Analysis]
35 Chew C, Shih V, Han Z. Evaluation of antibiotic appropriateness at an outpatient oncology centre. J Oncol Pharm Pract 2022;:10781552221087604. [PMID: 35306916 DOI: 10.1177/10781552221087604] [Reference Citation Analysis]
36 Zingel R, Bohlken J, Kostev K. Association Between Inflammatory Bowel Disease and Dementia: A Retrospective Cohort Study. J Alzheimers Dis 2021;80:1471-8. [PMID: 33720902 DOI: 10.3233/JAD-210103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Wang X, Xu L, Wang T, Xu J, Fan F, Zhang Y, Wang J, Cao Q. Pulsatilla decoction alleviates colitis by enhancing autophagy and regulating PI3K‑Akt‑mTORC1 signaling pathway. Mol Med Rep 2022;25:108. [PMID: 35103289 DOI: 10.3892/mmr.2022.12624] [Reference Citation Analysis]
38 Tan C, Fan H, Ding J, Han C, Guan Y, Zhu F, Wu H, Liu Y, Zhang W, Hou X, Tan S, Tang Q. ROS-responsive nanoparticles for oral delivery of luteolin and targeted therapy of ulcerative colitis by regulating pathological microenvironment. Materials Today Bio 2022;14:100246. [DOI: 10.1016/j.mtbio.2022.100246] [Reference Citation Analysis]
39 Lucafò M, Franzin M, Lagatolla C, Franca R, Bramuzzo M, Stocco G, Decorti G. Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients. Clin Transl Sci 2020;13:238-59. [PMID: 31675176 DOI: 10.1111/cts.12722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Sandborn WJ, Nguyen DD, Beattie DT, Brassil P, Krey W, Woo J, Situ E, Sana R, Sandvik E, Pulido-Rios MT, Bhandari R, Leighton JA, Ganeshappa R, Boyle DL, Abhyankar B, Kleinschek MA, Graham RA, Panes J. Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme. J Crohns Colitis 2020;14:1202-13. [PMID: 32161949 DOI: 10.1093/ecco-jcc/jjaa049] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 19.0] [Reference Citation Analysis]
41 Judge C, McGettigan N, Ryan T, Hazel K, Singh P, Parihar V, Stack R, O'Connor A, Dunne C, Cullen G, Egan L, Harewood G, MacCarthy F, McKiernan S, Mulcahy H, Murray F, Patchett S, Sheridan J, Cheriyan D, Farrell R, Keohane J, Kelly O, McNamara D, Ryan B, O'Morain C, Sengupta S, O'Toole A, Buckley M, McCarthy J, Doherty G, Kevans D, Slattery E. Irish data on the safety and efficacy of vedolizumab in the treatment of inflammatory bowel disease. Scand J Gastroenterol 2020;55:786-94. [PMID: 32544012 DOI: 10.1080/00365521.2020.1779340] [Reference Citation Analysis]
42 Hassan-Zahraee M, Ye Z, Xi L, Baniecki ML, Li X, Hyde CL, Zhang J, Raha N, Karlsson F, Quan J, Ziemek D, Neelakantan S, Lepsy C, Allegretti JR, Romatowski J, Scherl EJ, Klopocka M, Danese S, Chandra DE, Schoenbeck U, Vincent MS, Longman R, Hung KE. Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis. Inflamm Bowel Dis 2021:izab193. [PMID: 34427649 DOI: 10.1093/ibd/izab193] [Reference Citation Analysis]
43 Murthy SK, Feuerstein JD, Nguyen GC, Velayos FS. AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. Gastroenterology 2021;161:1043-1051.e4. [PMID: 34416977 DOI: 10.1053/j.gastro.2021.05.063] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Khan N, Pernes T, Weiss A, Trivedi C, Patel M, Xie D, Yang YX. Incidence of Infections and Malignancy Among Elderly Male Patients with IBD Exposed to Vedolizumab, Prednisone, and 5-ASA Medications: A Nationwide Retrospective Cohort Study. Adv Ther 2021;38:2586-98. [PMID: 33844132 DOI: 10.1007/s12325-021-01713-x] [Reference Citation Analysis]
45 Ghosh S, Sanchez Gonzalez Y, Zhou W, Clark R, Xie W, Louis E, Loftus EV Jr, Panes J, Danese S. Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis. J Crohns Colitis 2021:jjab099. [PMID: 34107013 DOI: 10.1093/ecco-jcc/jjab099] [Reference Citation Analysis]
46 Levy LC, Coburn ES, Choi S, Holubar SD. The management of the hospitalized ulcerative colitis patient: the medical-surgical conundrum. Current Opinion in Gastroenterology 2020;36:265-76. [DOI: 10.1097/mog.0000000000000637] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Henry C, Bassignani A, Berland M, Langella O, Sokol H, Juste C. Modern Metaproteomics: A Unique Tool to Characterize the Active Microbiome in Health and Diseases, and Pave the Road towards New Biomarkers—Example of Crohn’s Disease and Ulcerative Colitis Flare-Ups. Cells 2022;11:1340. [DOI: 10.3390/cells11081340] [Reference Citation Analysis]
48 Rowan C, Ungaro R, Mehandru S, Colombel JF. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis. Expert Opin Pharmacother 2022. [PMID: 35503955 DOI: 10.1080/14656566.2022.2071605] [Reference Citation Analysis]
49 Kelly N. Complexities of the Microbiome: Jaundice in Patient With Ulcerative Colitis. J Nurse Pract 2020;16:e133-6. [PMID: 32837404 DOI: 10.1016/j.nurpra.2020.04.025] [Reference Citation Analysis]
50 Hong SJ, Zenger C, Pecoriello J, Pang A, Vallely M, Hudesman DP, Chang S, Axelrad JE. Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy. Inflamm Bowel Dis 2022:izac035. [PMID: 35262671 DOI: 10.1093/ibd/izac035] [Reference Citation Analysis]
51 Guo Z, Bai Y, Zhang Z, Mei H, Li J, Pu Y, Zhao N, Gao W, Wu F, He B, Xie J. Thermosensitive polymer hydrogel as a physical shield on colonic mucosa for colitis treatment. J Mater Chem B 2021;9:3874-84. [PMID: 33928321 DOI: 10.1039/d1tb00499a] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Brar MS, de Buck van Overstraeten A, Baxter NN. Rectal Cancer Incidence is Low Following Rectal Diversion or Subtotal Colectomy for IBD: Results of a Population-based Study. J Crohns Colitis 2021:jjab090. [PMID: 34165532 DOI: 10.1093/ecco-jcc/jjab090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Grossberg LB, Farraye FA, Papamichael K, Cheifetz AS, Feuerstein JD. A Survey Study of Gastroenterologists' Views on Dysplasia Surveillance and Chromoendoscopy in IBD. Inflamm Bowel Dis 2020;26:e59-61. [PMID: 32304571 DOI: 10.1093/ibd/izaa079] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Antonelli E, Torti G, Bassotti G. Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis.J Clin Gastroenterol. 2019;53:635-640. [PMID: 31373941 DOI: 10.1097/MCG.0000000000001250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
55 Alshahrani KS, Almohaya AM, Hussein RS, Ali RH, Tsay GJ. Enthesitis in Bowel-Associated Dermatosis-Arthritis Syndrome in an Ulcerative Colitis Patient. Case Reports in Rheumatology 2022;2022:1-4. [DOI: 10.1155/2022/4556250] [Reference Citation Analysis]
56 Moktan VP, Koop AH, Olson MT, Lewis MD, Gomez V, Farraye FA. An Unusual Cause of Large Bowel Obstruction in a Patient With Ulcerative Colitis. ACG Case Rep J 2021;8:e00638. [PMID: 34307716 DOI: 10.14309/crj.0000000000000638] [Reference Citation Analysis]
57 Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol 2021;14:17562848211059954. [PMID: 34917173 DOI: 10.1177/17562848211059954] [Reference Citation Analysis]
58 Ran Z, Wu K, Matsuoka K, Jeen YT, Wei SC, Ahuja V, Chen M, Hu PJ, Andoh A, Kim HJ, Yang SK, Watanabe M, Ng SC, Hibi T, Hilmi IN, Suzuki Y, Han DS, Leung WK, Sollano J, Ooi CJ, Qian J. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol 2021;36:637-45. [PMID: 32672839 DOI: 10.1111/jgh.15185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Barnhill MS, Steinberg JM, Jennings JJ, Lewis JH. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. Curr Gastroenterol Rep 2020;22:47. [PMID: 32671616 DOI: 10.1007/s11894-020-00781-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
60 Lin L, Wyness SP, Jensen R, Bird J, Norgyal T, Jensen G, Johnson LM. Comparison of Next-Generation Assays for Fecal Calprotectin vs the PhiCal Assay. Am J Clin Pathol 2021:aqab114. [PMID: 34390332 DOI: 10.1093/ajcp/aqab114] [Reference Citation Analysis]
61 Cohan JN, Ozanne EM, Hofer RK, Kelly YM, Kata A, Larsen C, Finlayson E. Ileostomy or ileal pouch-anal anastomosis for ulcerative colitis: patient participation and decisional needs. BMC Gastroenterol 2021;21:347. [PMID: 34538236 DOI: 10.1186/s12876-021-01916-0] [Reference Citation Analysis]
62 Bai L, Scott MKD, Steinberg E, Kalesinskas L, Habtezion A, Shah NH, Khatri P. Computational drug repositioning of atorvastatin for ulcerative colitis. J Am Med Inform Assoc 2021;28:2325-35. [PMID: 34529084 DOI: 10.1093/jamia/ocab165] [Reference Citation Analysis]
63 Zhang D, Yan P, Han T, Cheng X, Li J. Identification of key genes and biological processes contributing to colitis associated dysplasia in ulcerative colitis. PeerJ 2021;9:e11321. [PMID: 33987007 DOI: 10.7717/peerj.11321] [Reference Citation Analysis]
64 Lightner AL, Vaidya P, Allende D, Gorgun E. Endoscopic submucosal dissection is safe and feasible, allowing for ongoing surveillance and organ preservation in patients with inflammatory bowel disease. Colorectal Dis 2021;23:2100-7. [PMID: 34021968 DOI: 10.1111/codi.15746] [Reference Citation Analysis]
65 Lang-Schwarz C, Agaimy A, Atreya R, Becker C, Danese S, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, Nagtegaal I, Neurath MF, Oberhuber G, Peyrin-Biroulet L, Rath T, Riddell R, Rubio CA, Sheahan K, Tilg H, Villanacci V, Westerhoff M, Vieth M. Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. Virchows Arch 2021;478:581-94. [PMID: 33373023 DOI: 10.1007/s00428-020-02982-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
66 Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology 2021;161:47-65. [PMID: 33940007 DOI: 10.1053/j.gastro.2021.04.063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Singh S, Kim J, Zhu W, Dulai PS, Sandborn WJ, Jairath V. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther 2020;52:481-91. [PMID: 32573825 DOI: 10.1111/apt.15876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Wetwittayakhlang P, Golovics PA, Afif W, Bessissow T, Lakatos PL. Tofacitinib-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis. ACG Case Rep J 2021;8:e00678. [PMID: 34840995 DOI: 10.14309/crj.0000000000000678] [Reference Citation Analysis]
69 Long MD, Rubin DT. Histologic Remission in Ulcerative Colitis: Are We There Yet? Am J Gastroenterol 2019;114:713-5. [PMID: 31021831 DOI: 10.14309/ajg.0000000000000235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
70 Lopes EW, Lebwohl B, Burke KE, Ivey KL, Ananthakrishnan AN, Lochhead P, Richter JM, Ludvigsson JF, Willett WC, Chan AT, Khalili H. Dietary Gluten Intake Is Not Associated With Risk of Inflammatory Bowel Disease in US Adults Without Celiac Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00339-6. [PMID: 33775898 DOI: 10.1016/j.cgh.2021.03.029] [Reference Citation Analysis]
71 Yang T, Ma X, Wang R, Liu H, Wei S, Jing M, Li H, Zhao Y. Berberine inhibits IFN-γ signaling pathway in DSS-induced ulcerative colitis. Saudi Pharmaceutical Journal 2022. [DOI: 10.1016/j.jsps.2022.03.015] [Reference Citation Analysis]
72 Armuzzi A, DiBonaventura MD, Tarallo M, Lucas J, Bluff D, Hoskin B, Bargo D, Cappelleri JC, Quirk D, Salese L. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLoS One 2020;15:e0227914. [PMID: 31945774 DOI: 10.1371/journal.pone.0227914] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
73 Lu TX, Dapas M, Lin E, Peters T, Sakuraba A. The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies. Gut 2020:gutjnl-2020-321609. [PMID: 33334900 DOI: 10.1136/gutjnl-2020-321609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
74 Welty M, Mesana L, Padhiar A, Naessens D, Diels J, van Sanden S, Pacou M. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Curr Med Res Opin 2020;36:595-606. [PMID: 31960724 DOI: 10.1080/03007995.2020.1716701] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
75 George LA, Cross RK. Treatment of Ulcerative Colitis with Steroids (in Whom, How Long, What Dose, What Form). Gastroenterology Clinics of North America 2020;49:705-16. [DOI: 10.1016/j.gtc.2020.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Olortegui KS, Graham A, Hyman N. Staging Considerations for the Ileal Pouch-Anal Anastomosis. J Gastrointest Surg. [DOI: 10.1007/s11605-022-05317-w] [Reference Citation Analysis]
77 Conrad MA, Kelsen JR. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. Curr Gastroenterol Rep 2020;22:36. [PMID: 32542562 DOI: 10.1007/s11894-020-00773-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
78 Danese S, Subramaniam K, Van Zyl J, Adsul S, Lindner D, Roth J, Vermeire S. Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. Aliment Pharmacol Ther 2021;53:265-72. [PMID: 33210333 DOI: 10.1111/apt.16160] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Wang Y, Makadia R, Knoll C, Hardin J, Voss EA, Fife D, Davis K, Sloan S. Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration. BMC Gastroenterol 2021;21:121. [PMID: 33731009 DOI: 10.1186/s12876-021-01708-6] [Reference Citation Analysis]
80 Lang-Schwarz C, Adler W, Geppert M, Seitz G, Sterlacci W, Falkeis-Veits C, Veits L, Drgac J, Melcher B, Lang-Schwarz K, Nikolaev S, Dregelies T, Krugmann J, Vieth M. Sporadic adenoma or ulcerative colitis associated neoplasia? The endoscopist's information has an impact on diagnosis and patient management. Pathol Res Pract 2020;216:153162. [PMID: 32916446 DOI: 10.1016/j.prp.2020.153162] [Reference Citation Analysis]
81 Shah SC, Itzkowitz SH. Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. Gastroenterology 2021:S0016-5085(21)03707-0. [PMID: 34757143 DOI: 10.1053/j.gastro.2021.10.035] [Reference Citation Analysis]
82 Nones RB, Fleshner PR, Queiroz NSF, Cheifetz AS, Spinelli A, Danese S, Peyrin-Biroulet L, Papamichael K, Kotze PG. Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. J Clin Med 2021;10:5642. [PMID: 34884344 DOI: 10.3390/jcm10235642] [Reference Citation Analysis]
83 Wei W, Zhang Y, Li R, Cao Y, Yan X, Ma Y, Zhang Y, Yang M, Zhang M. Oral Delivery of Pterostilbene by L-Arginine-Mediated “Nano-Bomb” Carrier for the Treatment of Ulcerative Colitis. IJN 2022;Volume 17:603-16. [DOI: 10.2147/ijn.s347506] [Reference Citation Analysis]
84 Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, Petersen A, Charles L, Huang V, Usiskin K, Wolf DC, D'Haens G. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. J Crohns Colitis 2021;15:1120-9. [PMID: 33438008 DOI: 10.1093/ecco-jcc/jjab012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
85 Kondo A, Ma S, Lee MYY, Ortiz V, Traum D, Schug J, Wilkins B, Terry NA, Lee H, Kaestner KH. Highly Multiplexed Image Analysis of Intestinal Tissue Sections in Patients With Inflammatory Bowel Disease. Gastroenterology 2021:S0016-5085(21)03480-6. [PMID: 34529988 DOI: 10.1053/j.gastro.2021.08.055] [Reference Citation Analysis]
86 Sebastian S, Lisle J, Subramanian S, Dhar A, Shenoy A, Limdi J, Butterworth J, Allen PB, Samuel S, Moran G, Shenderey R, Parkes G, Raine T, Lobo AJ, Kennedy NA. Practice pattern variability in the management of acute severe colitis: a UK provider survey. Frontline Gastroenterol 2020;11:272-9. [PMID: 32587670 DOI: 10.1136/flgastro-2019-101277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
87 Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther 2020;51:271-80. [PMID: 31660640 DOI: 10.1111/apt.15555] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
88 Karpin J, Rodriguez TG, Traboulsi C, Rai V, Gibbons RD, Rubin DT. Assessment of Comorbid Depression and Anxiety in Inflammatory Bowel Disease Using Adaptive Testing Technology. Crohns Colitis 360 2021;3:otaa095. [PMID: 34746788 DOI: 10.1093/crocol/otaa095] [Reference Citation Analysis]
89 Israel A, Christensen B, El Jurdi K, Rai V, Ollech JE, Cohen RD, Sakuraba A, Dalal SR, Rubin DT. Follow-Up of Patients With Ulcerative Colitis and Histological Normalization. Clin Gastroenterol Hepatol 2020;18:987-988.e1. [PMID: 31228567 DOI: 10.1016/j.cgh.2019.06.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
90 Lightner AL, Vogel JD, Carmichael JC, Keller DS, Shah SA, Mahadevan U, Kane SV, Paquette IM, Steele SR, Feingold DL. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn's Disease. Dis Colon Rectum. 2020;63:1028-1052. [PMID: 32692069 DOI: 10.1097/dcr.0000000000001716] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
91 Seong G, Song JH, Kim JE, Kim TJ, Kim ER, Hong SN, Chang DK, Kim SH, Ha SY, Kim YH. Histologic Activity and Steroid Use History Are Risk Factors of Clinical Relapse in Ulcerative Colitis With Mayo Endoscopic Subscore of 0 or 1. Inflamm Bowel Dis 2022:izac075. [PMID: 35396998 DOI: 10.1093/ibd/izac075] [Reference Citation Analysis]
92 Viscido A, Valvano M, Stefanelli G, Capannolo A, Castellini C, Onori E, Ciccone A, Vernia F, Latella G. Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis. BMC Gastroenterol 2022;22:92. [PMID: 35240984 DOI: 10.1186/s12876-022-02157-5] [Reference Citation Analysis]
93 Liu Y, Xu F, Wheaton AG, Greenlund KJ, Thomas CW. The association between inflammatory bowel disease and migraine or severe headache among US adults: Findings from the National Health Interview Survey, 2015-2016. Headache 2021;61:612-9. [PMID: 33756009 DOI: 10.1111/head.14087] [Reference Citation Analysis]
94 Tong X, Zheng Y, Li Y, Xiong Y, Chen D. Soluble ligands as drug targets for treatment of inflammatory bowel disease. Pharmacol Ther 2021;226:107859. [PMID: 33895184 DOI: 10.1016/j.pharmthera.2021.107859] [Reference Citation Analysis]
95 Barnes EL, Loftus EV Jr, Kappelman MD. Effects of Race and Ethnicity on Diagnosis and Management of Inflammatory Bowel Diseases. Gastroenterology 2021;160:677-89. [PMID: 33098884 DOI: 10.1053/j.gastro.2020.08.064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
96 Wijnands AM, Mahmoud R, Lutgens MWMD, Oldenburg B. Surveillance and management of colorectal dysplasia and cancer in inflammatory bowel disease: Current practice and future perspectives. Eur J Intern Med 2021;93:35-41. [PMID: 34481721 DOI: 10.1016/j.ejim.2021.08.010] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
97 Li Y, Li N, Liu J, Wang T, Dong R, Ge D, Peng G. Gegen Qinlian Decoction Alleviates Experimental Colitis and Concurrent Lung Inflammation by Inhibiting the Recruitment of Inflammatory Myeloid Cells and Restoring Microbial Balance. JIR 2022;Volume 15:1273-91. [DOI: 10.2147/jir.s352706] [Reference Citation Analysis]
98 Lei H, Crawford MS, McCole DF. JAK-STAT Pathway Regulation of Intestinal Permeability: Pathogenic Roles and Therapeutic Opportunities in Inflammatory Bowel Disease. Pharmaceuticals (Basel) 2021;14:840. [PMID: 34577540 DOI: 10.3390/ph14090840] [Reference Citation Analysis]
99 Azimirad M, Yadegar A, Gholami F, Shahrokh S, Asadzadeh Aghdaei H, Ianiro G, Suzuki H, Cammarota G, Zali MR. Treatment of Recurrent Clostridioides difficile Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease. J Inflamm Res 2020;13:563-70. [PMID: 32982371 DOI: 10.2147/JIR.S265520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Dulai PS, Jairath V. A Microsimulation Model to Project the 5-Year Impact of Using Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Acute Flares. Dig Dis Sci 2021;66:3740-52. [PMID: 33185788 DOI: 10.1007/s10620-020-06707-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
101 Wyant T, Yang L, Lirio RA, Rosario M. Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease. J Clin Pharmacol 2021;61:1174-81. [PMID: 33908636 DOI: 10.1002/jcph.1877] [Reference Citation Analysis]
102 Lin H, Bai Z, Wu Q, Chu G, Zhang Y, Guo X, Qi X. Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study. Front Public Health 2022;10:851295. [PMID: 35359771 DOI: 10.3389/fpubh.2022.851295] [Reference Citation Analysis]
103 Zhang XY, Dong HC, Wang WF, Zhang Y. Risk of venous thromboembolism in children and adolescents with inflammatory bowel disease: A systematic review and meta-analysis. World J Gastroenterol 2022; 28(16): 1705-1717 [DOI: 10.3748/wjg.v28.i16.1705] [Reference Citation Analysis]
104 Hendler SA, Barber GE, Okafor PN, Chang MS, Limsui D, Limketkai BN. Cytomegalovirus infection is associated with worse outcomes in inflammatory bowel disease hospitalizations nationwide. Int J Colorectal Dis 2020;35:897-903. [PMID: 32124046 DOI: 10.1007/s00384-020-03536-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
105 Jansson-Knodell CL, Harris CE, Loftus EV Jr, Walker RC, Enzler MJ, Virk A. Histoplasmosis in Inflammatory Bowel Disease with Tumor Necrosis Factor-Alpha Inhibitors: Safe to Continue Biologics? Dig Dis Sci 2021;66:190-8. [PMID: 32144603 DOI: 10.1007/s10620-020-06181-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Youssef ME, Abd El-Fattah EE, Abdelhamid AM, Eissa H, El-Ahwany E, Amin NA, Hetta HF, Mahmoud MH, Batiha GE, Gobba N, Ahmed Gaafar AG, Saber S. Interference With the AMPKα/mTOR/NLRP3 Signaling and the IL-23/IL-17 Axis Effectively Protects Against the Dextran Sulfate Sodium Intoxication in Rats: A New Paradigm in Empagliflozin and Metformin Reprofiling for the Management of Ulcerative Colitis. Front Pharmacol 2021;12:719984. [PMID: 34489707 DOI: 10.3389/fphar.2021.719984] [Reference Citation Analysis]
107 Zhang W, Chao X, Wu JQ, Ma XB, Yang YL, Wu Y, Lin JC. Exploring the Potential Mechanism of Guchang Zhixie Wan for Treating Ulcerative Colitis by Comprehensive Network Pharmacological Approaches and Molecular Docking Validation as Well as Cell Experiments. Chem Biodivers 2021;18:e2000810. [PMID: 33251769 DOI: 10.1002/cbdv.202000810] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 van der Laan JJH, van der Waaij AM, Gabriëls RY, Festen EAM, Dijkstra G, Nagengast WB. Endoscopic imaging in inflammatory bowel disease: current developments and emerging strategies. Expert Rev Gastroenterol Hepatol 2021;15:115-26. [PMID: 33094654 DOI: 10.1080/17474124.2021.1840352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
109 Chan WPW, Tan YB, Shim HH, Kaltenbach T, Soetikno R. Practice pattern variability among gastroenterologists in colorectal cancer surveillance and management of colorectal dysplasia in inflammatory bowel disease. J Dig Dis 2021;22:463-72. [PMID: 34173325 DOI: 10.1111/1751-2980.13031] [Reference Citation Analysis]
110 Li W, Zhang L, Xu Q, Yang W, Zhao J, Ren Y, Yu Z, Ma L. Taxifolin Alleviates DSS-Induced Ulcerative Colitis by Acting on Gut Microbiome to Produce Butyric Acid. Nutrients 2022;14:1069. [DOI: 10.3390/nu14051069] [Reference Citation Analysis]
111 Axelrad JE, Shah SC. Diagnosis and management of inflammatory bowel disease-associated neoplasia: considerations in the modern era. Therap Adv Gastroenterol 2020;13:1756284820920779. [PMID: 32523622 DOI: 10.1177/1756284820920779] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Shahrokh S, Qobadighadikolaei R, Abbasinazari M, Haghazali M, Asadzadeh Aghdaei H, Abdi S, Balaii H, Khanzadeh-Moghaddam N, Zali MR. Efficacy and Safety of Melatonin as an Adjunctive Therapy on Clinical, Biochemical, and Quality of Life in Patients with Ulcerative Colitis. Iran J Pharm Res 2021;20:197-205. [PMID: 34567156 DOI: 10.22037/ijpr.2020.113822.14508] [Reference Citation Analysis]
113 Flicek CB, Sowa NA, Long MD, Herfarth HH, Dorn SD. Implementing Collaborative Care Management of Behavioral Health for Patients with Inflammatory Bowel Disease. Inflamm Intest Dis. [DOI: 10.1159/000521285] [Reference Citation Analysis]
114 Vitello A, Shahini E, Macaluso FS, Morreale GC, Sinagra E, Pallio S, Maida M. Endoscopic surveillance of colorectal cancer in inflammatory bowel diseases: a review of the literature. Expert Rev Anticancer Ther 2020;20:851-63. [PMID: 32811225 DOI: 10.1080/14737140.2020.1813030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
115 Alipour O, Lee V, Tejura TK, Wilson ML, Memel Z, Cho J, Cologne K, Hwang C, Shao L. The assessment of sarcopenia using psoas muscle thickness per height is not predictive of post-operative complications in IBD. Scand J Gastroenterol 2021;:1-7. [PMID: 34344243 DOI: 10.1080/00365521.2021.1958368] [Reference Citation Analysis]
116 Kornbluth A. Histologic Healing in Ulcerative Colitis: Benefits. And Risks. Was Voltaire Right? Inflamm Bowel Dis 2020;26:1730-2. [PMID: 32031216 DOI: 10.1093/ibd/izz333] [Reference Citation Analysis]
117 Siegel CA, Bernstein CN. Identifying Patients With Inflammatory Bowel Diseases at High vs Low Risk of Complications. Clinical Gastroenterology and Hepatology 2020;18:1261-7. [DOI: 10.1016/j.cgh.2019.11.034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
118 Yuan X, Chen B, Duan Z, Xia Z, Ding Y, Chen T, Liu H, Wang B, Yang B, Wang X, Liu S, Zhou JY, Liu Y, Wang Q, Shen Z, Xiao J, Shang H, Liu W, Shi G, Zhu L, Chen Y. Depression and anxiety in patients with active ulcerative colitis: crosstalk of gut microbiota, metabolomics and proteomics. Gut Microbes 2021;13:1987779. [PMID: 34806521 DOI: 10.1080/19490976.2021.1987779] [Reference Citation Analysis]
119 Kochar B, Orkaby AR, Ananthakrishnan AN, Ritchie CS. Frailty in inflammatory bowel diseases: an emerging concept. Therap Adv Gastroenterol 2021;14:17562848211025474. [PMID: 34594400 DOI: 10.1177/17562848211025474] [Reference Citation Analysis]
120 Samimi N, Sepehrimanesh M, Koohi-Hosseinabadi O, Homayounfar R, Mokhtari M, Farjam M. The Therapeutic Effect of Shark Liver Oil in a Rat Model of Acetic Acid-Induced Ulcerative Colitis. Evid Based Complement Alternat Med 2020;2020:2419230. [PMID: 33149751 DOI: 10.1155/2020/2419230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
121 Kirchgesner J, Desai RJ, Schneeweiss MC, Beaugerie L, Kim SC, Schneeweiss S. Emulation of a randomized controlled trial in ulcerative colitis with US and French claims data: Infliximab with thiopurines compared to infliximab monotherapy. Pharmacoepidemiol Drug Saf 2021. [PMID: 34498314 DOI: 10.1002/pds.5356] [Reference Citation Analysis]
122 Schreiber S, Ben-Horin S, Leszczyszyn J, Dudkowiak R, Lahat A, Gawdis-Wojnarska B, Pukitis A, Horynski M, Farkas K, Kierkus J, Kowalski M, Lee SJ, Kim SH, Suh JH, Kim MR, Lee SG, Ye BD, Reinisch W. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology 2021;160:2340-53. [PMID: 33676969 DOI: 10.1053/j.gastro.2021.02.068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
123 Bhama AR, Kapadia MR. Management of Dysplasia in Ulcerative Colitis. J Laparoendosc Adv Surg Tech A 2021;31:855-60. [PMID: 34252316 DOI: 10.1089/lap.2020.0974] [Reference Citation Analysis]
124 Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Hibi T, D'Haens GR, Tuttle JL, Krueger K, Friedrich S, Durante M, Arora V, Naegeli AN, Schmitz J, Feagan BG. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31289-1. [PMID: 32950748 DOI: 10.1016/j.cgh.2020.09.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
125 Papamichael K, Cheifetz AS. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. Curr Opin Rheumatol 2020;32:371-9. [PMID: 32412995 DOI: 10.1097/BOR.0000000000000713] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
126 Si Y, Shao L, Gao S, Wen H. Suppository treatment in ulcerative proctitis. Eur J Inflamm 2021;19:205873922110151. [DOI: 10.1177/20587392211015108] [Reference Citation Analysis]
127 Afzali A. Inflammatory bowel disease during pregnancy: management of a disease flare or remission. Current Opinion in Gastroenterology 2019;35:281-7. [DOI: 10.1097/mog.0000000000000541] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
128 Ogino H, Morikubo H, Fukaura K, Okui T, Gardiner S, Sugiyama N, Yoshii N, Kawaguchi T, Chen H, Nonnenmacher E, Setoguchi S, Nakashima N, Kobayashi T. Validation of a claims-based algorithm to identify cases of ulcerative colitis in Japan. J Gastroenterol Hepatol 2021. [PMID: 34738649 DOI: 10.1111/jgh.15732] [Reference Citation Analysis]
129 Zhang S, Cho WJ, Jin AT, Kok LY, Shi Y, Heller DE, Lee YL, Zhou Y, Xie X, Korzenik JR, Lennerz JK, Traverso G. Heparin-Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine. Adv Healthc Mater 2020;9:e2000536. [PMID: 32597571 DOI: 10.1002/adhm.202000536] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
130 Alipour O, Gualti A, Shao L, Zhang B. Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease. BMC Gastroenterol 2021;21:312. [PMID: 34344314 DOI: 10.1186/s12876-021-01883-6] [Reference Citation Analysis]
131 Rubín de Célix C, Chaparro M, Moreno JA, Santander C, Gisbert JP. Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real-life experience. Scand J Gastroenterol 2021;56:806-11. [PMID: 33905275 DOI: 10.1080/00365521.2021.1918758] [Reference Citation Analysis]
132 Heron V, Loftus EV Jr. Nonbiologic Immune Suppression in Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:731-8. [PMID: 33121692 DOI: 10.1016/j.gtc.2020.07.003] [Reference Citation Analysis]
133 Sah J, Teeple A, Muser E, Gutierrez C, Dassopoulos T. Treatment persistence and maintenance dose titration among ulcerative colitis on biologics: a pooled study of three United States claim databases. Curr Med Res Opin 2022;:1-25. [PMID: 35475385 DOI: 10.1080/03007995.2022.2071041] [Reference Citation Analysis]
134 Weissman S, Systrom HK, Aziz M, El-Dallal M, Lee-Smith W, Sciarra M, Feuerstein JD. Colorectal Cancer Prevention in Inflammatory Bowel Disease: A Systematic Analysis of the Overall Quality of Guideline Recommendations. Inflamm Bowel Dis 2021:izab164. [PMID: 34245270 DOI: 10.1093/ibd/izab164] [Reference Citation Analysis]
135 AlAskar D, AlSardi M, Al Sulais E, Mosli M, AlAmeel T. Risk of neutropenia in inflammatory bowel disease patients treated with TNF inhibitors: A single-center, retrospective cohort study. Saudi J Gastroenterol 2020. [PMID: 32496224 DOI: 10.4103/sjg.SJG_41_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
136 Cohen NA, Micic DM, Sakuraba A. Factors associated with poor compliance amongst hospitalized, predominantly adolescent pediatric Crohn's disease patients. Ann Med 2022;54:886-92. [PMID: 35352625 DOI: 10.1080/07853890.2022.2057582] [Reference Citation Analysis]
137 Yao H, Stidham RW, Gao Z, Gryak J, Najarian K. Motion-based camera localization system in colonoscopy videos. Med Image Anal 2021;73:102180. [PMID: 34303888 DOI: 10.1016/j.media.2021.102180] [Reference Citation Analysis]
138 Shen Z, Zheng K, Zou J, Gu P, Xing J, Zhang L, Zhu L, Shen H. Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial. Trials 2021;22:55. [PMID: 33441157 DOI: 10.1186/s13063-020-05012-8] [Reference Citation Analysis]
139 Fernandes SA, Rossoni C, Koch VW, Imbrizi M, Evangelista-Poderoso R, Pinto LP, Magro DO. Phase angle through electrical bioimpedance as a predictor of cellularity in inflammatory bowel disease. Artif Intell Gastroenterol 2021; 2(4): 111-123 [DOI: 10.35712/aig.v2.i4.111] [Reference Citation Analysis]
140 Shen Z, Sun P, Jiang M, Zhen Z, Liu J, Ye M, Huang W. Endoscopic retrograde appendicitis therapy versus laparoscopic appendectomy versus open appendectomy for acute appendicitis: a pilot study. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02139-7] [Reference Citation Analysis]
141 Toma L, Dodot M, Zgura A, Bacalbasa N, Silaghi A, Simu R, Isac T, Mercan-Stanciu A. Calprotectin in viral systemic infections-COVID-19 versus hepatitis C virus. Clin Exp Med 2021. [PMID: 34254197 DOI: 10.1007/s10238-021-00743-7] [Reference Citation Analysis]
142 Wang X, Yang YM, Yang T, An LY, Chen XZ, Qi YX, He HY, Fan HB, Sun DL. Evaluation of pharmacotherapy recommendations in guidelines for inflammatory bowel disease. J Clin Pharm Ther 2021;46:599-609. [PMID: 33543814 DOI: 10.1111/jcpt.13368] [Reference Citation Analysis]
143 Shaffer SR, Traboulsi C, Krugliak Cleveland N, Rubin DT. Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis. ACG Case Rep J 2021;8:e00604. [PMID: 34007860 DOI: 10.14309/crj.0000000000000604] [Reference Citation Analysis]
144 Magro F, Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis? United European Gastroenterol J 2020;8:755-63. [PMID: 32552501 DOI: 10.1177/2050640620935732] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
145 Lewis JD, Cross RK, Long M, Singh S, Herfarth H, Weiss A, Buchner A. High Degree of Practice Variability in Colonic Dysplasia Surveillance for Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2022:izab347. [PMID: 35022777 DOI: 10.1093/ibd/izab347] [Reference Citation Analysis]
146 Rezk MF, Pieper B. Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review. Adv Ther 2020;37:3732-45. [PMID: 32740789 DOI: 10.1007/s12325-020-01437-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
147 Akiyama S, Sakamoto T, Steinberg JM, Saito Y, Tsuchiya K. Evolving roles of magnifying endoscopy and endoscopic resection for neoplasia in inflammatory bowel diseases. World J Gastrointest Oncol 2022; 14(3): 646-653 [DOI: 10.4251/wjgo.v14.i3.646] [Reference Citation Analysis]
148 Schauer C, Avery V, Seleq S, Garg P, Wang MTM, Chieng M, Rowan C, Sekra A, Lane M, Walmsley R. A comparison of intravenous methylprednisolone and hydrocortisone for the treatment of acute inflammatory bowel disease. J Gastroenterol Hepatol 2021. [PMID: 33939853 DOI: 10.1111/jgh.15535] [Reference Citation Analysis]
149 Palasik BN, Wang H. Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis. J Pharm Pract 2020;:897190020953019. [PMID: 32873116 DOI: 10.1177/0897190020953019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
150 Lichtenstein GR, Cohen BL, Salese L, Soonasra A, Modesto I, Wang W, Woodworth DA, Chan G, Quirk D, Su C, Peyrin-biroulet L. 706 Impact of Baseline Corticosteroid Therapy on Tofacitinib Induction Efficacy and Infection Risk in Patients With Ulcerative Colitis: Data From Global Clinical Trials. Am J Gastroenterol 2019;114:S415-S415. [DOI: 10.14309/01.ajg.0000592360.46252.8a] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
151 Wark G, Samocha-Bonet D, Ghaly S, Danta M. The Role of Diet in the Pathogenesis and Management of Inflammatory Bowel Disease: A Review. Nutrients 2020;13:E135. [PMID: 33396537 DOI: 10.3390/nu13010135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
152 Yen HH, Chen MW, Chang YY, Huang HY, Hsu TC, Chen YY. Predictive values of stool-based tests for mucosal healing among Taiwanese patients with ulcerative colitis: a retrospective cohort analysis. PeerJ 2020;8:e9537. [PMID: 32742803 DOI: 10.7717/peerj.9537] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
153 Mishra S, Mandavdhare HS, Singh H, Choudhury A, Shah J, Ram S, Kalsi D, Samanta J, Prasad KK, Sharma AK, Dutta U, Sharma V. Adjuvant use of combination of antibiotics in acute severe ulcerative colitis: A placebo controlled randomized trial. Expert Rev Anti Infect Ther 2021;19:949-55. [PMID: 33245002 DOI: 10.1080/14787210.2021.1856656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
154 Kotze PG, Steinwurz F, Francisconi C, Zaltman C, Pinheiro M, Salese L, Ponce de Leon D. Review of the epidemiology and burden of ulcerative colitis in Latin America. Therap Adv Gastroenterol 2020;13:1756284820931739. [PMID: 32695230 DOI: 10.1177/1756284820931739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
155 Yang X, Geng J, Meng H. Glucocorticoid receptor modulates dendritic cell function in ulcerative colitis. Histol Histopathol 2020;35:1379-89. [PMID: 32706033 DOI: 10.14670/HH-18-241] [Reference Citation Analysis]
156 Chen DL, Dai YC, Zheng L, Chen YL, Zhang YL, Tang ZP. Features of the gut microbiota in ulcerative colitis patients with depression: A pilot study. Medicine (Baltimore) 2021;100:e24845. [PMID: 33607855 DOI: 10.1097/MD.0000000000024845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis.Nat Rev Dis Primers. 2020;6:74. [PMID: 32913180 DOI: 10.1038/s41572-020-0205-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 26.0] [Reference Citation Analysis]
158 Sun Y, Geng J, Chen X, Chen H, Wang X, Chen J, Li X, Hesketh T. Association Between Inflammatory Bowel Disease and Dementia: A Longitudinal Cohort Study. Inflamm Bowel Dis 2021:izab300. [PMID: 34849925 DOI: 10.1093/ibd/izab300] [Reference Citation Analysis]
159 Fang JM, Lamps L, Yeboah-Korang A, Cheng J, Westerhoff M. De Novo Inflammatory Bowel Disease Rarely Occurs During Posttransplant Immunosuppression. Am J Clin Pathol 2021:aqab084. [PMID: 34124746 DOI: 10.1093/ajcp/aqab084] [Reference Citation Analysis]
160 Rogler G, Scharl M, Spalinger M, Yilmaz B, Zaugg M, Hersberger M, Schreiner P, Biedermann L, Herfarth H. Diet and Inflammatory Bowel Disease: What Quality Standards Should Be Applied in Clinical and Laboratory Studies? Mol Nutr Food Res 2021;65:e2000514. [PMID: 33433954 DOI: 10.1002/mnfr.202000514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Vavricka SR, Greuter T, Cohen BL, Reinisch W, Steinwurz F, Fellmann M, Guo X, Lawendy N, Paulissen J, Peyrin-biroulet L. Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study. Therap Adv Gastroenterol 2022;15:175628482210908. [DOI: 10.1177/17562848221090834] [Reference Citation Analysis]
162 Lin M, Dong L, Chen Q, Xu H, Han X, Luo R, Pu X, Qi S, Nie W, Ma M, Wang Y, Gao F, Zhang J. Lentinan-Based Oral Nanoparticle Loaded Budesonide With Macrophage-Targeting Ability for Treatment of Ulcerative Colitis. Front Bioeng Biotechnol 2021;9:702173. [PMID: 34513811 DOI: 10.3389/fbioe.2021.702173] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Yin AL, Hachuel D, Pollak JP, Scherl EJ, Estrin D. Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review. J Med Internet Res. 2019;21:e14630. [PMID: 31429410 DOI: 10.2196/14630] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
164 Rubin DT, Sninsky C, Siegmund B, Sans M, Hart A, Bressler B, Bouhnik Y, Armuzzi A, Afzali A. International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey. Inflamm Bowel Dis 2021:izab006. [PMID: 33512475 DOI: 10.1093/ibd/izab006] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
165 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastro 2019;17:435-48. [DOI: 10.1007/s11938-019-00249-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
166 Mazzurana L, Bonfiglio F, Forkel M, D'Amato M, Halfvarson J, Mjösberg J. Crohn's Disease Is Associated With Activation of Circulating Innate Lymphoid Cells. Inflamm Bowel Dis 2021;27:1128-38. [PMID: 33295628 DOI: 10.1093/ibd/izaa316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
167 Gutierrez Becker B, Arcadu F, Thalhammer A, Gamez Serna C, Feehan O, Drawnel F, Oh YS, Prunotto M. Training and deploying a deep learning model for endoscopic severity grading in ulcerative colitis using multicenter clinical trial data. Ther Adv Gastrointest Endosc. 2021;14:2631774521990623. [PMID: 33718871 DOI: 10.1177/2631774521990623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
168 Chen Y, Li H, Lai L, Feng Q, Shen J. Identification of Common Differentially Expressed Genes and Potential Therapeutic Targets in Ulcerative Colitis and Rheumatoid Arthritis. Front Genet 2020;11:572194. [PMID: 33262784 DOI: 10.3389/fgene.2020.572194] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Gupta V, Mohsen W, Chapman TP, Satsangi J. Predicting Outcome in Acute Severe Colitis-Controversies in Clinical Practice in 2021. J Crohns Colitis 2021;15:1211-21. [PMID: 33388777 DOI: 10.1093/ecco-jcc/jjaa265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
170 Wang B, Liu Y, Sun J, Zhang N, Zheng X, Liu Q. Exploring the Potential Mechanism of Xiaokui Jiedu Decoction for Ulcerative Colitis Based on Network Pharmacology and Molecular Docking. J Healthc Eng 2021;2021:1536337. [PMID: 34733451 DOI: 10.1155/2021/1536337] [Reference Citation Analysis]
171 Qiu P, Liu L, Fang J, Zhang M, Wang H, Peng Y, Chen M, Liu J, Wang F, Zhao Q. Identification of Pharmacological Autophagy Regulators of Active Ulcerative Colitis. Front Pharmacol 2021;12:769718. [PMID: 34925026 DOI: 10.3389/fphar.2021.769718] [Reference Citation Analysis]
172 Lu H, Lin J, Xu C, Sun M, Zuo K, Zhang X, Li M, Huang H, Li Z, Wu W, Feng B, Liu Z. Cyclosporine modulates neutrophil functions via the SIRT6-HIF-1α-glycolysis axis to alleviate severe ulcerative colitis. Clin Transl Med 2021;11:e334. [PMID: 33634990 DOI: 10.1002/ctm2.334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Lu J, Zhou J, Wang L, Zhong C, Chen X, Jia B. Efficacy and safety evaluation of acupoint embedding for patients with ulcerative colitis: A protocol of systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e21812. [PMID: 32846819 DOI: 10.1097/MD.0000000000021812] [Reference Citation Analysis]
174 Wu X, Liang TY, Wang Z, Chen G. The role of hyperbaric oxygen therapy in inflammatory bowel disease: a narrative review. Med Gas Res 2021;11:66-71. [PMID: 33818446 DOI: 10.4103/2045-9912.311497] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Magro F, Cordeiro G, Dias AM, Estevinho MM. Inflammatory Bowel Disease - Non-biological treatment. Pharmacol Res 2020;160:105075. [PMID: 32653651 DOI: 10.1016/j.phrs.2020.105075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
176 Holubar SD, Lightner AL, Poylin V, Vogel JD, Gaertner W, Davis B, Davis KG, Mahadevan U, Shah SA, Kane SV, Steele SR, Paquette IM, Feingold DL; Prepared on behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis. Dis Colon Rectum 2021;64:783-804. [PMID: 33853087 DOI: 10.1097/DCR.0000000000002037] [Reference Citation Analysis]
177 Lan YZ, Bai YL, Zhu XD. Integrated Traditional Chinese and Western medicine for ulcerative colitis with diabetes: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e24444. [PMID: 33530250 DOI: 10.1097/MD.0000000000024444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Gonçalves BP, Flauzino T, Inoue CJ, de Paula JCC, Galvão TC, de Alcantara CC, Miyazaki PK, Rosa L, Westmore S, Lozovoy MAB, Reiche EMV, Simão ANC. IL6 genetic variants haplotype is associated with susceptibility and disease activity but not with therapy response in patients with inflammatory bowel disease. Int J Colorectal Dis 2021;36:383-93. [PMID: 33047210 DOI: 10.1007/s00384-020-03743-3] [Reference Citation Analysis]
179 Yao H, Najarian K, Gryak J, Bishu S, Rice MD, Waljee AK, Wilkins HJ, Stidham RW. Fully automated endoscopic disease activity assessment in ulcerative colitis. Gastrointest Endosc 2021;93:728-736.e1. [PMID: 32810479 DOI: 10.1016/j.gie.2020.08.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
180 Shah SC, Itzkowitz SH. Reappraising Risk Factors for Inflammatory Bowel Disease-associated Neoplasia: Implications for Colonoscopic Surveillance in IBD. J Crohns Colitis 2020;14:1172-7. [PMID: 32150256 DOI: 10.1093/ecco-jcc/jjaa040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
181 Molander P, Kemppainen H, Ilus T, Sipponen T. Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases. Scand J Gastroenterol 2020;55:34-40. [PMID: 31841064 DOI: 10.1080/00365521.2019.1701070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
182 Rabbenou W, Ullman TA. Risk of Colon Cancer and Recommended Surveillance Strategies in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:791-807. [PMID: 33121696 DOI: 10.1016/j.gtc.2020.08.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
183 Pavan E, Damazo AS, Arunachalam K, Almeida POA, Oliveira DM, Venturini CL, Figueiredo FF, Cruz TCDD, Silva JVD, Martins DTO. Copaifera malmei Harms leaves infusion attenuates TNBS-ulcerative colitis through modulation of cytokines, oxidative stress and mucus in experimental rats. J Ethnopharmacol 2021;267:113499. [PMID: 33091486 DOI: 10.1016/j.jep.2020.113499] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
184 Kochar B, Pate V, Kappelman MD, Long MD, Ananthakrishnan AN, Chan AT, Sandler RS. Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-TNF Agents in Older Adults. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00927-7. [PMID: 34481954 DOI: 10.1016/j.cgh.2021.08.047] [Reference Citation Analysis]
185 Naganuma M. Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis. J Gastroenterol 2020;55:1013-22. [PMID: 32778960 DOI: 10.1007/s00535-020-01713-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
186 Kaenkumchorn T, Wahbeh G. Ulcerative Colitis: Making the Diagnosis. Gastroenterol Clin North Am 2020;49:655-69. [PMID: 33121687 DOI: 10.1016/j.gtc.2020.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Ollech JE, Normatov I, Peleg N, Wang J, Patel SA, Rai V, Yi Y, Singer J, Dalal SR, Sakuraba A, Cohen RD, Rubin DT, Pekow J. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology 2021;19:104-10. [DOI: 10.1016/j.cgh.2020.02.035] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
188 Ghiassian SD, Voitalov I, Withers JB, Santolini M, Saleh A, Akmaev VR. Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis. Translational Research 2022. [DOI: 10.1016/j.trsl.2022.03.006] [Reference Citation Analysis]
189 Boeri M, Myers K, Ervin C, Marren A, DiBonaventura M, Cappelleri JC, Hauber B, Rubin DT. Patient and physician preferences for ulcerative colitis treatments in the United States. Clin Exp Gastroenterol 2019;12:263-78. [PMID: 31354328 DOI: 10.2147/CEG.S206970] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
190 Nigam GB, Nayeemuddin S, Kontopantelis E, Hayee B, Limdi JK. UK National Survey of Gastroenterologists' attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Frontline Gastroenterol 2021;12:22-9. [PMID: 33493247 DOI: 10.1136/flgastro-2019-101372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
191 Johnson LM, White SK, Schmidt RL. Are calprotectin and lactoferrin equivalent screening tests for inflammatory bowel disease? Clin Chim Acta 2020;510:191-5. [PMID: 32673669 DOI: 10.1016/j.cca.2020.07.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 Bajaj J, Brenner D, Cai Q, Cash B, Crowell M, Dibaise J, Gallegos-orozco J, Gardner T, Gyawali C, Ha C, Holtmann G, Jamil L, Kaplan G, Karsan H, Kinoshita Y, Lebwohl B, Leontiadis G, Lichtenstein G, Longstreth G, Muthusamy V, Oxentenko A, Pimentel M, Pisegna J, Rubenstein J, Russo M, Saini S, Samadder N, Shaukat A, Simren M, Stevens T, Valdovinos M, Vargas H, Spiegel B, Lacy B. Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology. Am J Gastroenterol 2020;115:1007-18. [DOI: 10.14309/ajg.0000000000000709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
193 Lu M, Zhang T, Lu Z, Wang W, Chen T, Cao Z. A comparison of the efficacy and safety of complementary and alternative therapies for ulcerative colitis: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e21219. [PMID: 32664174 DOI: 10.1097/MD.0000000000021219] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
194 Bhattacharya A, Osterman MT. Biologic Therapy for Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:717-29. [PMID: 33121691 DOI: 10.1016/j.gtc.2020.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
195 Zhang J, Wang X, Xu L, Zhang Z, Wang F, Tang X. Investigation of Potential Genetic Biomarkers and Molecular Mechanism of Ulcerative Colitis Utilizing Bioinformatics Analysis. Biomed Res Int 2020;2020:4921387. [PMID: 32190668 DOI: 10.1155/2020/4921387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
196 Shi J, Ma W, Tang H. Research progress of phosphodiesterase inhibitors in inflammatory bowel disease treatment. Zhejiang Da Xue Xue Bao Yi Xue Ban 2021;50:659-65. [PMID: 34986542 DOI: 10.3724/zdxbyxb-2021-0170] [Reference Citation Analysis]
197 Pang L, Liu H, Liu Z, Tan J, Zhou LY, Qiu Y, Lin X, He J, Li X, Lin S, Ghosh S, Mao R, Chen M. Role of Telemedicine in Inflammatory Bowel Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials. J Med Internet Res 2022;24:e28978. [PMID: 35323120 DOI: 10.2196/28978] [Reference Citation Analysis]
198 Sun W, Lirio RA, Schneider J, Aubrecht J, Kadali H, Baratta M, Gulati P, Suri A, Lin T, Vasudevan R, Rosario M. Assessment of Vedolizumab Disease-Drug-Drug Interaction Potential in Patients With Inflammatory Bowel Diseases. Clin Pharmacol Drug Dev 2021;10:734-47. [PMID: 33331142 DOI: 10.1002/cpdd.891] [Reference Citation Analysis]
199 Lin YF, Sung CM, Ke HM, Kuo CJ, Liu WA, Tsai WS, Lin CY, Cheng HT, Lu MJ, Tsai IJ, Hsieh SY. The rectal mucosal but not fecal microbiota detects subclinical ulcerative colitis. Gut Microbes 2021;13:1-10. [PMID: 33525983 DOI: 10.1080/19490976.2020.1832856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Wijnands AM, de Jong ME, Lutgens MWMD, Hoentjen F, Elias SG, Oldenburg B; Dutch Initiative on Crohn and Colitis (ICC). Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis. Gastroenterology 2021;160:1584-98. [PMID: 33385426 DOI: 10.1053/j.gastro.2020.12.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
201 Pai RK, Hartman DJ, Rivers CR, Regueiro M, Schwartz M, Binion DG, Pai RK. Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2020;18:2510-2517.e5. [DOI: 10.1016/j.cgh.2019.12.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
202 Rubin DT, Griffith J, Zhang Q, Hepp Z, Keshishian A. The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies. Inflamm Bowel Dis 2021;27:1201-9. [PMID: 33107564 DOI: 10.1093/ibd/izaa270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
203 Sousa P, Ministro P, Armuzzi A, Dignass A, Høivik ML, Barreiro-de Acosta M, Vavricka S, Saad-Hossne R, Gustavo Kotze P, Peyrin-Biroulet L, Magro F. Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. Dig Liver Dis 2021:S1590-8658(21)00315-7. [PMID: 34187768 DOI: 10.1016/j.dld.2021.05.038] [Reference Citation Analysis]
204 Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med 2019;9:E94. [PMID: 31905945 DOI: 10.3390/jcm9010094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
205 Sicilia B, Vicente R, Arias L, Echarri A, Zabana Y, Mañosa M, Beltrán B, Barreiro-de Acosta M; en nombre de GETECCU. Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa - GETECCU) on dysplasia screening in inflammatory bowel disease patients. Gastroenterol Hepatol 2021;44:435-47. [PMID: 33592179 DOI: 10.1016/j.gastrohep.2020.12.011] [Reference Citation Analysis]
206 Harrison N, Humes R, Singla M. Skip, Stop, Switch, and Spare: Steroid Therapy in Inflammatory Bowel Disease. Am J Gastroenterol 2021;116:1819-21. [PMID: 34279011 DOI: 10.14309/ajg.0000000000001380] [Reference Citation Analysis]
207 Ghiassian SD, Withers JB, Santolini M, Saleh A, Akmaev VR. Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis. Transl Res 2021:S1931-5244(21)00106-7. [PMID: 33965585 DOI: 10.1016/j.trsl.2021.04.010] [Reference Citation Analysis]
208 Palacios Argueta P, Salazar M, Attar B, Simons-Linares R, Shen B. 90-Day Specific Readmission for Clostridium difficile Infection After Hospitalization With an Inflammatory Bowel Disease Flare: Outcomes and Risk Factors. Inflamm Bowel Dis 2021;27:530-7. [PMID: 32812037 DOI: 10.1093/ibd/izaa224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
209 Gupta A, Yu A, Peyrin-Biroulet L, Ananthakrishnan AN. Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2020;. [PMID: 33010406 DOI: 10.1016/j.cgh.2020.09.046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
210 Bhattacharya S, Cross RK. Medical treatment of ulcerative colitis. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100863] [Reference Citation Analysis]
211 Dou B, Hu W, Song M, Lee RJ, Zhang X, Wang D. Anti-inflammation of Erianin in dextran sulphate sodium-induced ulcerative colitis mice model via collaborative regulation of TLR4 and STAT3. Chem Biol Interact 2020;324:109089. [PMID: 32272095 DOI: 10.1016/j.cbi.2020.109089] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
212 Meserve J, Singh S. Pathologist, Meet Picasso! Virtual Chromoendoscopy for Detecting Histologic Remission in Ulcerative Colitis. Gastroenterology 2021;160:1469-72. [PMID: 33508287 DOI: 10.1053/j.gastro.2021.01.213] [Reference Citation Analysis]
213 Hu AB, Burke KE, Kochar B, Ananthakrishnan AN. Yield of Random Biopsies During Colonoscopies in Inflammatory Bowel Disease Patients Undergoing Dysplasia Surveillance. Inflamm Bowel Dis 2021;27:779-86. [PMID: 32812048 DOI: 10.1093/ibd/izaa205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
214 Salem G, Ding K, Sakuraba A, Cohen R. Role of topical tacrolimus in the management of proctitis, perianal manifestations in Crohn's disease, and chronic pouchitis: a systematic review. J Investig Med 2021:jim-2020-001699. [PMID: 33622709 DOI: 10.1136/jim-2020-001699] [Reference Citation Analysis]
215 Hisabe T, Matsui T, Yamasaki K, Morokuma T, Aomi K, Yoshizawa N, Takatsu N, Yao K, Ueki T, Futami K, Tanabe H, Iwashita A. Possible Earlier Diagnosis of Ulcerative Colitis-Associated Neoplasia: A Retrospective Analysis of Interval Cases during Surveillance. J Clin Med 2021;10:1927. [PMID: 33946906 DOI: 10.3390/jcm10091927] [Reference Citation Analysis]
216 Yang DH, Park SJ, Kim HS, Park YS, Park DI, Lee KM, Jung SA, Choi CH, Koo JS, Cheon JH, Yang SK, Kim WH, Kim J, Kim H, Ryan Choi CH;  Korean Association for the Study of the Intestinal Diseases (KASID) study. High-Definition Chromoendoscopy Versus High-Definition White Light Colonoscopy for Neoplasia Surveillance in Ulcerative Colitis: A Randomized Controlled Trial. Am J Gastroenterol. 2019;114:1642-1648. [PMID: 31567166 DOI: 10.14309/ajg.0000000000000341] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
217 Smith R, Hubers J, Farraye FA, Sampene E, Hayney MS, Caldera F. Accuracy of Self-Reported Vaccination Status in a Cohort of Patients with Inflammatory Bowel Disease. Dig Dis Sci 2021;66:2935-41. [PMID: 32995995 DOI: 10.1007/s10620-020-06631-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
218 Ko JZ, Johnson S, Dave M. Efficacy and Safety of Mesenchymal Stem/Stromal Cell Therapy for Inflammatory Bowel Diseases: An Up-to-Date Systematic Review.Biomolecules. 2021;11. [PMID: 33440772 DOI: 10.3390/biom11010082] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
219 Palchaudhuri S, Albenberg L, Lewis JD. Diet Recommendations for Hospitalized Patients With Inflammatory Bowel Disease: Better Options Than Nil Per Os. Crohns Colitis 360 2020;2:otaa059. [PMID: 33954288 DOI: 10.1093/crocol/otaa059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
220 Blackwell J, Selinger C, Raine T, Parkes G, Smith MA, Pollok R. Steroid use and misuse: a key performance indicator in the management of IBD. Frontline Gastroenterol 2021;12:207-13. [PMID: 33907617 DOI: 10.1136/flgastro-2019-101288] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
221 Bogach J, Pond G, Eskicioglu C, Simunovic M, Seow H. Extent of Surgical Resection in Inflammatory Bowel Disease Associated Colorectal Cancer: a Population-Based Study. J Gastrointest Surg 2021. [PMID: 33559097 DOI: 10.1007/s11605-021-04913-6] [Reference Citation Analysis]
222 Ahmed EA, Abdelatty K, Mahdy RE, Emara DM, Header DA. Computed tomography enterocolongraphy in assessment of degree of ulcerative colitis activity. Int J Clin Pract 2021;:e14626. [PMID: 34258846 DOI: 10.1111/ijcp.14626] [Reference Citation Analysis]
223 Clarke WT, Feuerstein JD. Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments. World J Gastroenterol 2019; 25(30): 4148-4157 [PMID: 31435169 DOI: 10.3748/wjg.v25.i30.4148] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
224 Vachon A, Scott FI. The treatment approach to inflammatory bowel disease in 2020. Curr Opin Gastroenterol 2020;36:247-56. [PMID: 32452863 DOI: 10.1097/MOG.0000000000000653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
225 Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, Lazin K, Klassen P, Naik SU, Cabell CH, Sandborn WJ. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. J Crohns Colitis 2021;15:950-9. [PMID: 33475734 DOI: 10.1093/ecco-jcc/jjab016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Neri M, Guidi L, Gasbarrini A, Armuzzi A. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therap Adv Gastroenterol 2021;14:17562848211006669. [PMID: 33995579 DOI: 10.1177/17562848211006669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
227 Jena A, Mishra S, Singh AK, Sekar A, Sharma V. Cytomegalovirus in ulcerative colitis: An evidence-based approach to diagnosis and treatment. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2032662] [Reference Citation Analysis]
228 McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet 2021;398:803-16. [PMID: 34454676 DOI: 10.1016/S0140-6736(21)00438-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
229 de Jong ME, Kanne H, Nissen LHC, Drenth JPH, Derikx LAAP, Hoentjen F. Increased risk of high-grade dysplasia and colorectal cancer in inflammatory bowel disease patients with recurrent low-grade dysplasia. Gastrointest Endosc 2020;91:1334-1342.e1. [PMID: 31923409 DOI: 10.1016/j.gie.2019.12.041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
230 Rong JM, Luo J, Huang Q, Miao YL. Individualized selection of biological agents in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2021; 29(15): 893-900 [DOI: 10.11569/wcjd.v29.i15.893] [Reference Citation Analysis]
231 Dubinsky MC, Irving PM, Panaccione R, Naegeli AN, Potts-Bleakman A, Arora V, Shan M, Travis S. Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults. J Patient Rep Outcomes 2022;6:31. [PMID: 35362902 DOI: 10.1186/s41687-022-00439-w] [Reference Citation Analysis]
232 Kasuga K, Yamada M, Shida D, Tagawa T, Takamaru H, Sekiguchi M, Sakamoto T, Uraoka T, Sekine S, Kanemitsu Y, Saito Y. Treatment outcomes of endoscopic submucosal dissection and surgery for colorectal neoplasms in patients with ulcerative colitis. United European Gastroenterol J 2021. [PMID: 34232561 DOI: 10.1002/ueg2.12118] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
233 Pilon D, Ding Z, Muser E, Obando C, Voelker J, Manceur AM, Kinkead F, Lafeuille MH, Lefebvre P. Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population. Curr Med Res Opin 2020;36:1285-94. [PMID: 32427006 DOI: 10.1080/03007995.2020.1771293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
234 Du W, Han W, Dong J. Long-term oral vancomycin for refractory inflammatory bowel diseases without Clostridium difficile infection: Lessons from primary sclerosing cholangitis. Med Hypotheses 2020;144:110211. [PMID: 33254520 DOI: 10.1016/j.mehy.2020.110211] [Reference Citation Analysis]
235 Fletcher J, Cooper SC, Ghosh S, Hewison M. The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management. Nutrients. 2019;11. [PMID: 31067701 DOI: 10.3390/nu11051019] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 17.0] [Reference Citation Analysis]
236 Aardoom MA, Klomberg RCW, Kemos P, Ruemmele FM, van Ommen H, de Ridder L, Croft NM. The incidence and characteristics of venous thromboembolisms in paediatric-onset inflammatory bowel disease; a prospective international cohort study based on the PIBD-SETQuality Safety Registry. J Crohns Colitis 2021:jjab171. [PMID: 34599822 DOI: 10.1093/ecco-jcc/jjab171] [Reference Citation Analysis]
237 Linssen MD, Hooghiemstra WTR, Jorritsma-Smit A, Allersma DP, Dijkstra G, Nagengast WB. Development and Characterisation of Antibody-Based Optical Imaging Probes for Inflammatory Bowel Disease. Pharmaceuticals (Basel) 2021;14:922. [PMID: 34577622 DOI: 10.3390/ph14090922] [Reference Citation Analysis]
238 Norton B, Sullivan A, Senior J, Candela N, Jason M, Weyant K. Vedolizumab for Moderate to Severe Ulcerative Colitis: A Review for Nurse Practitioners. The Journal for Nurse Practitioners 2022. [DOI: 10.1016/j.nurpra.2021.12.001] [Reference Citation Analysis]
239 Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00222-6. [PMID: 33684552 DOI: 10.1016/j.cgh.2021.02.043] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
240 Tran V, Limketkai BN, Sauk JS. IBD in the Elderly: Management Challenges and Therapeutic Considerations. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0720-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
241 Damião AOMC, Queiroz NSF. Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough. Clin Colon Rectal Surg 2022;35:032-43. [DOI: 10.1055/s-0041-1740036] [Reference Citation Analysis]
242 Mourad FH, Hashash JG, Kariyawasam VC, Leong RW. Ulcerative Colitis and Cytomegalovirus Infection: From A to Z. J Crohns Colitis. 2020;14:1162-1171. [PMID: 32103246 DOI: 10.1093/ecco-jcc/jjaa036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
243 Leifeld L, Denzer U, Frieling T, Jakobs R, Koop H, van Leeuwen P, Madisch A, Rosien U, Stier A, Siegmund B, Tappe U, Lammert F, Lynen Jansen P. [Quality management in the field of gastroenterology - Proposals of the Quality Commission of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) for Outpatient and Inpatient Quality Assurance]. Z Gastroenterol 2021;59:665-76. [PMID: 34255315 DOI: 10.1055/a-1451-6350] [Reference Citation Analysis]
244 Clark-Snustad K, Butnariu M, Afzali A. Women's Health and Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:769-89. [PMID: 33121695 DOI: 10.1016/j.gtc.2020.07.004] [Reference Citation Analysis]
245 Jung KH, Kim J, Lee HS, Choi J, Jang SJ, Jung J, Kim MJ, Chong YP, Lee SO, Choi SH, Kim YS, Woo JH, Park SH, Yang DH, Ye BD, Yang SK, Kim SH. Clinical Implications of the CMV-Specific T-Cell Response and Local or Systemic CMV Viral Replication in Patients With Moderate to Severe Ulcerative Colitis. Open Forum Infect Dis 2019;6:ofz526. [PMID: 31893211 DOI: 10.1093/ofid/ofz526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
246 Liu M, Xie W, Wan X, Deng T. Clostridium butyricum protects intestinal barrier function via upregulation of tight junction proteins and activation of the Akt/mTOR signaling pathway in a mouse model of dextran sodium sulfate-induced colitis. Exp Ther Med 2020;20:10. [PMID: 32934675 DOI: 10.3892/etm.2020.9138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
247 Li PH, Tang Y, Wen HZ. Qingchang decoction retention enema may induce clinical and mucosal remission in left-sided ulcerative colitis: A case report. World J Clin Cases 2022; 10(11): 3573-3578 [DOI: 10.12998/wjcc.v10.i11.3573] [Reference Citation Analysis]
248 Goldowsky A, Sen R, Hoffman G, Feuerstein JD. Is there a standardized practice for the development of international ulcerative colitis and Crohn's disease treatment guidelines? Gastroenterol Rep (Oxf) 2021;9:408-17. [PMID: 34733526 DOI: 10.1093/gastro/goab009] [Reference Citation Analysis]
249 Chibbar R, Moss AC. Mesalamine in the Initial Therapy of Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:689-704. [PMID: 33121689 DOI: 10.1016/j.gtc.2020.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
250 Wang W, Cleveland NK, Ollech J, Rubin DT. Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis. ACG Case Rep J 2019;6:e00226. [PMID: 31750389 DOI: 10.14309/crj.0000000000000226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
251 Connor BA, Martin GJ, Riddle MS. Use of the Multiplex Diagnostic PCR Panel in Diarrheal Disease: Expert Guidance on the Interpretation of Results With a Focus on Travelers' Diarrhea. Am J Gastroenterol 2020;115:1553-5. [DOI: 10.14309/ajg.0000000000000735] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
252 Parigi TL, Roda G, Argollo M, Gilardi D, Danese S, Peyrin-biroulet L. Is there a role for therapeutic sphingolipids in inflammatory bowel disease? Expert Review of Gastroenterology & Hepatology 2020;14:47-54. [DOI: 10.1080/17474124.2020.1709446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
253 Sakellariou G, Schiepatti A, Scalvini D, Lusetti F, Fazzino E, Biagi F, Montecucco C. Musculoskeletal Ultrasound to Identify Subclinical Joint and Periarticular Involvement in Patients With Inflammatory Bowel Disease: A Systematic Literature Review. Front Med 2022;9:919521. [DOI: 10.3389/fmed.2022.919521] [Reference Citation Analysis]
254 Liu M, Li D, Hong X, Sun Z. Increased Risk for Dementia in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Population-Based Studies. Front Neurol 2022;13:813266. [DOI: 10.3389/fneur.2022.813266] [Reference Citation Analysis]
255 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
256 Bence CM, Traynor MD Jr, Polites SF, Ha D, Muenks P, St Peter SD, Landman MP, Densmore JC, Potter DD Jr. The incidence of venous thromboembolism in children following colorectal resection for inflammatory bowel disease: A multi-center study. J Pediatr Surg 2020;55:2387-92. [PMID: 32145975 DOI: 10.1016/j.jpedsurg.2020.02.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
257 Paridaens K, Fullarton JR, Travis SPL. Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. Curr Med Res Opin 2021;37:1891-900. [PMID: 34404286 DOI: 10.1080/03007995.2021.1968813] [Reference Citation Analysis]
258 Shaffer SR, Rubin DT. Response to Tetangco and Hanauer. Am J Gastroenterol 2021;116:1959-60. [PMID: 34101668 DOI: 10.14309/ajg.0000000000001330] [Reference Citation Analysis]
259 Modi NB, Cheng X, Mattheakis L, Hwang CC, Nawabi R, Liu D, Gupta S. Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers. Clin Pharmacol Drug Dev 2021. [PMID: 33942566 DOI: 10.1002/cpdd.946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
260 Wyness SP, Lin L, Jensen R, Bird J, Norgyal T, Jensen G, Johnson LM. Clinical and Analytical Verification of an Automated Fecal Calprotectin Immunoassay with Extraction Device. J Appl Lab Med 2021;6:931-41. [PMID: 33582792 DOI: 10.1093/jalm/jfaa236] [Reference Citation Analysis]
261 Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
262 Rubalcava NS, Gadepalli SK, Criss CN, Moreno NA, Adler J, Geiger JD. Single-stage restorative proctocolectomy for ulcerative colitis in pediatric patients: a safe alternative. Pediatr Surg Int 2021;37:1453-9. [PMID: 34143272 DOI: 10.1007/s00383-021-04943-w] [Reference Citation Analysis]
263 Gordon M, Sinopoulou V, Iheozor-Ejiofor Z, Iqbal T, Allen P, Hoque S, Engineer J, Akobeng AK. Interventions for treating iron deficiency anaemia in inflammatory bowel disease. Cochrane Database Syst Rev 2021;1:CD013529. [PMID: 33471939 DOI: 10.1002/14651858.CD013529.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
264 Godínez-Méndez LA, Gurrola-Díaz CM, Zepeda-Nuño JS, Vega-Magaña N, Lopez-Roa RI, Íñiguez-Gutiérrez L, García-López PM, Fafutis-Morris M, Delgado-Rizo V. In Vivo Healthy Benefits of Galacto-Oligosaccharides from Lupinus albus (LA-GOS) in Butyrate Production through Intestinal Microbiota. Biomolecules 2021;11:1658. [PMID: 34827656 DOI: 10.3390/biom11111658] [Reference Citation Analysis]
265 Yen HH, Hsu TC, Chen MW, Su PY, Chen YY. Clinical features and treatment of inflammatory bowel disease in a low-incidence area: A hospital-based retrospective cohort study in Taiwan. Medicine (Baltimore) 2021;100:e25090. [PMID: 33725901 DOI: 10.1097/MD.0000000000025090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV Jr, Bhatia S, Agboton C, Rosario M, Chen C, Zhang W, Kisfalvi K, Sandborn WJ. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. J Crohns Colitis 2021:jjab133. [PMID: 34402887 DOI: 10.1093/ecco-jcc/jjab133] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 Axelrad JE, Sachs MC, Ludvigsson JF, Olén O; SWIBREG Study Group. A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data. Clin Epidemiol 2020;12:1059-72. [PMID: 33116900 DOI: 10.2147/CLEP.S265404] [Reference Citation Analysis]
268 Annese V. An update on treatment of ulcerative colitis. Expert Opinion on Orphan Drugs 2019;7:295-304. [DOI: 10.1080/21678707.2019.1638249] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
269 Yvellez OV, Rai V, Sossenheimer PH, Hart J, Turner JR, Weber C, El Jurdi K, Rubin DT. Cumulative Histologic Inflammation Predicts Colorectal Neoplasia in Ulcerative Colitis: A Validation Study. Inflamm Bowel Dis 2021;27:203-6. [PMID: 32152624 DOI: 10.1093/ibd/izaa047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
270 Dulai PS, Wong ECL, Reinisch W, Colombel JF, Marshall JK, Narula N. Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab. Inflamm Bowel Dis 2021:izab310. [PMID: 34967397 DOI: 10.1093/ibd/izab310] [Reference Citation Analysis]
271 Gupta S, Aihara H, Trivedi HD, Srivastava A, Allegretti JR, Hamilton MJ. Heading in the Right Dissection: Toward an Endoscopic Cancer Cure in a Patient with Long-Standing Ulcerative Colitis. Dig Dis Sci 2020;65:2818-22. [PMID: 32661762 DOI: 10.1007/s10620-020-06465-2] [Reference Citation Analysis]
272 Suzuki Y, Watanabe M, Matsui T, Motoya S, Hisamatsu T, Yuasa H, Tabira J, Isogawa N, Tsuchiwata S, Arai S, Hibi T. Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis. Inflamm Intest Dis 2019;4:131-43. [PMID: 31768386 DOI: 10.1159/000502144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
273 Pitman S, Jones C, Polyak S, Taylor A, Cerven-jenn D, Reist D. Exploring Cost Savings with Specialty Biologic Drugs Administered to Adult Inpatients with Inflammatory Bowel Disease. Hosp Pharm. [DOI: 10.1177/0018578720985430] [Reference Citation Analysis]
274 Bargo D, Tritton T, Cappelleri JC, DiBonaventura M, Smith TW, Tsuchiya T, Gardiner S, Modesto I, Holbrook T, Bluff D, Kobayashi T. Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use. Inflamm Intest Dis 2021;6:186-98. [PMID: 35083284 DOI: 10.1159/000519123] [Reference Citation Analysis]
275 Lu JJ, Maimaiti M, Liu H, Liu WD, Hui WJ, Huang XL, Gao F. Potential Biomarkers Associated with Differential Manifestations of Ulcerative Colitis (UC) in Uyghur and Han Population in China. J Inflamm Res 2021;14:7431-41. [PMID: 35002277 DOI: 10.2147/JIR.S335293] [Reference Citation Analysis]
276 Li F, Fu J, Fan L, Lu S, Zhang H, Wang X, Liu Z. Overexpression of circAtp9b in ulcerative colitis is induced by lipopolysaccharides and upregulates PTEN to promote the apoptosis of colonic epithelial cells. Exp Ther Med 2021;22:1404. [PMID: 34675997 DOI: 10.3892/etm.2021.10840] [Reference Citation Analysis]
277 Shaffer SR, Huang E, Patel S, Rubin DT. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol 2021;116:125-33. [PMID: 32947317 DOI: 10.14309/ajg.0000000000000847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
278 Ahmed W, Lukin DJ. Finding a Needle in the Haystack? Defining the Role of Random Biopsies in IBD Dysplasia Surveillance. Inflamm Bowel Dis 2021;27:787-90. [PMID: 32812050 DOI: 10.1093/ibd/izaa206] [Reference Citation Analysis]
279 Ungaro RC, Brenner EJ, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021;70:725-32. [PMID: 33082265 DOI: 10.1136/gutjnl-2020-322539] [Cited by in Crossref: 59] [Cited by in F6Publishing: 76] [Article Influence: 29.5] [Reference Citation Analysis]
280 Ge X, Jiang L, Yu W, Wu Y, Liu W, Qi W, Cao Q, Bai R, Zhou W. The importance of sarcopenia as a prognostic predictor of the clinical course in acute severe ulcerative colitis patients. Dig Liver Dis 2021;53:965-71. [PMID: 33934998 DOI: 10.1016/j.dld.2021.03.031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
281 Choi YI, Kim YJ, Chung JW, Kim KO, Kim H, Park RW, Park DK. Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study. JMIR Med Inform 2020;8:e15124. [PMID: 32293578 DOI: 10.2196/15124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
282 Jia X, Guo R, Hu Z, Liu J, Liu J, Li B, Yang Q, He J. Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis. Medicine (Baltimore) 2020;99:e22894. [PMID: 33126341 DOI: 10.1097/MD.0000000000022894] [Reference Citation Analysis]
283 Armuzzi A, Bouhnik Y, Cummings F, Bettey M, Pieper B, Kang T. Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice. Dig Liver Dis 2020;52:1259-65. [PMID: 32601035 DOI: 10.1016/j.dld.2020.06.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
284 Yang S, Yang S, Kwon Jo Y, Kim S, Jung Chang M, Choi J, Hee Cheon J, Yu YM. Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis. Ther Adv Chronic Dis 2021;12:20406223211041927. [PMID: 34729142 DOI: 10.1177/20406223211041927] [Reference Citation Analysis]
285 Bickston SJ, Patrone MV. Current Venous Thromboembolism Chemoprophylaxis Practices After Surgery for Inflammatory Bowel Diseases. Inflamm Bowel Dis 2022:izac086. [PMID: 35452122 DOI: 10.1093/ibd/izac086] [Reference Citation Analysis]
286 Alhalabi MM, Abbas AJ. Subcutaneous golimumab to treat a biological naïve chronically active ulcerative colitis child. A case report. Annals of Medicine and Surgery 2022;75:103456. [DOI: 10.1016/j.amsu.2022.103456] [Reference Citation Analysis]
287 Debnath P, Rathi PM. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflamm Intest Dis 2021;6:1-17. [PMID: 33850834 DOI: 10.1159/000512805] [Reference Citation Analysis]
288 Sattler L, Hanauer SB, Malter L. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Curr Gastroenterol Rep 2021;23:30. [PMID: 34913108 DOI: 10.1007/s11894-021-00829-y] [Reference Citation Analysis]
289 Domínguez-Díaz C, Varela-Trinidad GU, Muñoz-Sánchez G, Solórzano-Castanedo K, Avila-Arrezola KE, Iñiguez-Gutiérrez L, Delgado-Rizo V, Fafutis-Morris M. To Trap a Pathogen: Neutrophil Extracellular Traps and Their Role in Mucosal Epithelial and Skin Diseases. Cells 2021;10:1469. [PMID: 34208037 DOI: 10.3390/cells10061469] [Reference Citation Analysis]
290 Zhang B, Wang HE, Bai YM, Tsai SJ, Su TP, Chen TJ, Wang YP, Chen MH. Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study. Gut. 2020;. [PMID: 32576641 DOI: 10.1136/gutjnl-2020-320789] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 14.5] [Reference Citation Analysis]
291 Swier RM, Siebrasse A, Coscia E, Peery AF. Diet in Benign Colonic Disorders: A Narrative Review. Clinical Therapeutics 2022. [DOI: 10.1016/j.clinthera.2022.03.010] [Reference Citation Analysis]
292 Lightner AL, Vogler S, Mcmichael J, Jia X, Regueiro M, Qazi T, Steele SR. Dysplastic Progression to Adenocarcinoma is Equivalent in Ulcerative Colitis and Crohn’s Disease. Journal of Crohn's and Colitis 2021;15:24-34. [DOI: 10.1093/ecco-jcc/jjaa133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
293 Sharma A, Phulia A, Sethi RS. PET/computed tomography enterography. Nucl Med Commun 2021;42:694-8. [PMID: 33560721 DOI: 10.1097/MNM.0000000000001373] [Reference Citation Analysis]
294 Tetangco EP, Hanauer SB. 5-ASAs Combined With a Biologic or Tofacitinib: Predetermined Cost-Effectiveness? Am J Gastroenterol 2021;116:1958-9. [PMID: 34465697 DOI: 10.14309/ajg.0000000000001296] [Reference Citation Analysis]
295 Al Sulais E, AlAmeel T. Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease. Biologics 2020;14:1-11. [PMID: 32021084 DOI: 10.2147/BTT.S236433] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
296 Aoun R, Jabak S, Mourad FH, Francis FF, Regueiro M, Hashash JG. First or Second Biologic in Inflammatory Bowel Disease: Combination Therapy or Monotherapy? J Clin Gastroenterol 2021;55:740-6. [PMID: 34294654 DOI: 10.1097/MCG.0000000000001591] [Reference Citation Analysis]
297 Hibi T, Ishibashi T, Ikenoue Y, Yoshihara R, Nihei A, Kobayashi T. Ulcerative Colitis: Disease Burden, Impact on Daily Life, and Reluctance to Consult Medical Professionals: Results from a Japanese Internet Survey. Inflamm Intest Dis 2020;5:27-35. [PMID: 32232052 DOI: 10.1159/000505092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
298 Narula N, Hu A, Nguyen GC, Rangrej J, Marshall JK. Periodic Colonoscopies Are Associated with Improved Survival and Prognosis of Colorectal Cancer in Ulcerative Colitis. Dig Dis Sci 2021. [PMID: 34318355 DOI: 10.1007/s10620-021-07151-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
299 Panés J, Colombel JF, D'Haens GR, Schreiber S, Panaccione R, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Tanida S, Okuyama Y, Louis E, Armuzzi A, Ferrante M, Vogelsang H, Hibi T, Watanabe M, Lefebvre J, Finney-Hayward T, Sanchez Gonzalez Y, Doan TT, Mostafa NM, Ikeda K, Xie W, Huang B, Petersson J, Kalabic J, Robinson AM, Sandborn WJ. Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. Gastroenterology 2022:S0016-5085(22)00199-8. [PMID: 35227777 DOI: 10.1053/j.gastro.2022.02.033] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
300 Colombel JF, Osterman MT, Thorpe AJ, Salese L, Nduaka CI, Zhang H, Lawendy N, Friedman GS, Quirk D, Su C, Reinisch W. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2022;20:116-125.e5. [PMID: 33039585 DOI: 10.1016/j.cgh.2020.10.004] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
301 Thompson KM, Badizadegan K. Health economic analyses of secondary vaccine effects: a systematic review and policy insights. Expert Rev Vaccines 2021. [PMID: 34927511 DOI: 10.1080/14760584.2022.2017287] [Reference Citation Analysis]
302 Tarabar D, El Jurdi K, Traboulsi C, Yvellez O, Milenkovic Z, Petrovic S, Subotic B, Gils A, Brocic T, Brcerevic I, Latinovic O, Jocic T, Rubin DT. A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab. Inflammatory Bowel Diseases 2022. [DOI: 10.1093/ibd/izab328] [Reference Citation Analysis]
303 Yin J, Wei L, Wang N, Li X, Miao M. Efficacy and safety of adjuvant curcumin therapy in ulcerative colitis: A systematic review and meta-analysis. Journal of Ethnopharmacology 2022. [DOI: 10.1016/j.jep.2022.115041] [Reference Citation Analysis]
304 Oh GM, Moon W, Seo KI, Jung K, Kim JH, Kim SE, Park MI, Park SJ. Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study. Korean J Gastroenterol 2021;77:12-21. [PMID: 33361702 DOI: 10.4166/kjg.2020.0119] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
305 Hata K, Ishihara S, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Kunisaki R, Nakase H, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Shinozaki M, Ogata N, Moriichi K, Hirai F, Sugihara K, Hisamatsu T, Suzuki Y, Watanabe M, Hibi T. Long-Term Follow-Up of Targeted Biopsy Yield (LOFTY Study) in Ulcerative Colitis Surveillance Colonoscopy. J Clin Med 2020;9:E2286. [PMID: 32708456 DOI: 10.3390/jcm9072286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
306 Long MD, Smith TW, Dibonaventura M, Gruben D, Bargo D, Salese L, Quirk D. Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States. Inflamm Bowel Dis 2020;26:941-8. [PMID: 31560046 DOI: 10.1093/ibd/izz204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
307 Fiori G, Trovato C, Staiano T, Magarotto A, Stigliano V, Masci E, Ciuffi M, Rossi GB, Fantin A, Realdon S, Ugenti I, Cannizzaro R. Reorganization of the endoscopic activity of Cancer Institutes during phase II of the Covid-19 emergency. Dig Liver Dis 2020;52:1346-50. [PMID: 32601037 DOI: 10.1016/j.dld.2020.06.023] [Reference Citation Analysis]
308 Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Danese S, Rogers R, Bornstein JD, Chen J, Schreiber S, Sands BE, Lirio RA. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Gastroenterology 2021:S0016-5085(21)03126-7. [PMID: 34144047 DOI: 10.1053/j.gastro.2021.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
309 Hashash JG, Fadel CGA, Rimmani HH, Sharara AI. Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis. Ann Gastroenterol 2021;34:612-24. [PMID: 34475731 DOI: 10.20524/aog.2021.0645] [Reference Citation Analysis]
310 Inglet S, Winter B, Yost SE, Entringer S, Lian A, Biksacky M, Pitt RD, Mortensen W. Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature. Ann Pharmacother 2020;54:1109-43. [DOI: 10.1177/1060028020930189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
311 Park SB, Kim S, Lee J, Lee YJ, Baek DH, Seo GS, Kim ES, Kim S, Kim SY. Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02178-0] [Reference Citation Analysis]
312 Casali M, Lauri C, Altini C, Bertagna F, Cassarino G, Cistaro A, Erba AP, Ferrari C, Mainolfi CG, Palucci A, Prandini N, Baldari S, Bartoli F, Bartolomei M, D'Antonio A, Dondi F, Gandolfo P, Giordano A, Laudicella R, Massollo M, Nieri A, Piccardo A, Vendramin L, Muratore F, Lavelli V, Albano D, Burroni L, Cuocolo A, Evangelista L, Lazzeri E, Quartuccio N, Rossi B, Rubini G, Sollini M, Versari A, Signore A. State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation. Clin Transl Imaging 2021;9:299-339. [PMID: 34277510 DOI: 10.1007/s40336-021-00445-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
313 Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV Jr, Hart A, Dotan I, Damião AOMC, Judd DT, Guo X, Modesto I, Wang W, Panés J. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther 2021. [PMID: 34854095 DOI: 10.1111/apt.16712] [Reference Citation Analysis]
314 Wang JM, Lin SR, Zhu YB, Yuan J, Wang YM, Zhang Q, Xie LS, Li SH, Liu SQ, Yu SG, Wu QF. Proteomic analysis of lysine acetylation reveals that metabolic enzymes and heat shock proteins may be potential targets for DSS-induced mice colitis. Int Immunopharmacol 2021;101:108336. [PMID: 34768127 DOI: 10.1016/j.intimp.2021.108336] [Reference Citation Analysis]
315 Queiroz NSF, Graciolli CB, Sobrado CW. Exposure to Tofacitinib Not Related to Recurrence of Anal Premalignant Lesion: A Case Report. Inflamm Bowel Dis 2020;26:e155-6. [PMID: 32676668 DOI: 10.1093/ibd/izaa194] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
316 Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opinion on Biological Therapy 2020;20:363-78. [DOI: 10.1080/14712598.2019.1666101] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
317 Gordon M, Sinopoulou V, Akobeng AK, Pana M, Gasiea R, Moran GW. Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis. Cochrane Database Syst Rev 2022;4:CD007216. [PMID: 35388476 DOI: 10.1002/14651858.CD007216.pub2] [Reference Citation Analysis]
318 Shaffer SR, Erondu AI, Traboulsi C, Rai V, Krugliak Cleveland N, Israel A, Christensen B, Rubin DT. Achieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia. Inflamm Bowel Dis 2021:izab130. [PMID: 34037230 DOI: 10.1093/ibd/izab130] [Reference Citation Analysis]
319 Khan N, Mahmud N, Trivedi C, Reinisch W, Lewis JD. Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System. Gut 2021;70:1657-64. [PMID: 33753416 DOI: 10.1136/gutjnl-2021-324356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
320 Chhibba T, Ma C. Is there room for immunomodulators in ulcerative colitis? Expert Opin Biol Ther 2020;20:379-90. [PMID: 31874578 DOI: 10.1080/14712598.2020.1708896] [Reference Citation Analysis]
321 Glick LR, Cifu AS, Feld L. Ulcerative Colitis in Adults. JAMA 2020;324:1205. [DOI: 10.1001/jama.2020.11583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
322 Roberti R, Iannone LF, Palleria C, De Sarro C, Spagnuolo R, Barbieri MA, Vero A, Manti A, Pisana V, Fries W, Trifirò G, Naturale MD, Larussa T, De Francesco AE, Bosco V, Donato di Paola E, Citraro R, Luzza F, Bennardo L, Rodinò S, Doldo P, Spina E, Russo E, De Sarro G. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Curr Med Res Opin 2020;36:1457-63. [PMID: 32573307 DOI: 10.1080/03007995.2020.1786681] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
323 Dignass A, Waller J, Cappelleri JC, Modesto I, Kisser A, Dietz L, DiBonaventura M, Wood R, May M, Libutzki B, Bargo D. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. J Med Econ 2020;23:415-27. [PMID: 31858853 DOI: 10.1080/13696998.2019.1707210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
324 Malesza IJ, Malesza M, Krela-Kaźmierczak I, Zielińska A, Souto EB, Dobrowolska A, Eder P. Primary Humoral Immune Deficiencies: Overlooked Mimickers of Chronic Immune-Mediated Gastrointestinal Diseases in Adults. Int J Mol Sci 2020;21:E5223. [PMID: 32718006 DOI: 10.3390/ijms21155223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
325 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2019;17:420-33. [PMID: 31352659 DOI: 10.1007/s11938-019-00244-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
326 Lees CW, Deuring JJ, Chiorean M, Daperno M, Bonfanti G, Germino R, Brown PB, Modesto I, Edwards RA. Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies. Therap Adv Gastroenterol 2021;14:17562848211054710. [PMID: 35154388 DOI: 10.1177/17562848211054710] [Reference Citation Analysis]
327 Núñez F P, Krugliak Cleveland N, Quera R, Rubin DT. Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis. World J Gastroenterol 2021; 27(20): 2521-2530 [PMID: 34092973 DOI: 10.3748/wjg.v27.i20.2521] [Reference Citation Analysis]
328 Wetwittayakhlang P, Lontai L, Gonczi L, Golovics PA, Hahn GD, Bessissow T, Lakatos PL. Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology? J Clin Med 2021;10:5551. [PMID: 34884252 DOI: 10.3390/jcm10235551] [Reference Citation Analysis]
329 Danese S, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR, Peeva E, Vincent MS, Schoenbeck U, Ye Z, Hassan-Zahraee M, Rath N, Li G, Neelakantan S, Banfield C, Lepsy C, Chandra DE, Hung KE. Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00614-5. [PMID: 34126262 DOI: 10.1016/j.cgh.2021.06.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
330 Lee YI, Park Y, Park SJ, Kim TI, Kim WH, Cheon JH. Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis. Gut Liver 2021;15:232-42. [PMID: 32616683 DOI: 10.5009/gnl19433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
331 Yoon H, Jangi S, Dulai PS, Boland BS, Prokop LJ, Jairath V, Feagan BG, Sandborn WJ, Singh S. Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. Gastroenterology 2020;159:1262-1275.e7. [PMID: 32585306 DOI: 10.1053/j.gastro.2020.06.043] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
332 Dulai PS, Sandborn WJ, Murphy J. Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis. Clin Gastroenterol Hepatol 2021;19:1170-1179.e10. [PMID: 32437872 DOI: 10.1016/j.cgh.2020.05.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
333 Chen G, Yang Z, Wen D, Guo J, Xiong Q, Li P, Zhao L, Wang J, Wu C, Dong L. Polydatin has anti-inflammatory and antioxidant effects in LPS-induced macrophages and improves DSS-induced mice colitis. Immun Inflamm Dis 2021;9:959-70. [PMID: 34010516 DOI: 10.1002/iid3.455] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
334 Greenberg S, Herfarth HH, Barnes EL. Predictors of Inadequate Response to Budesonide Multimatrix in Real-World Patients with Ulcerative Colitis. Inflamm Intest Dis 2019;4:115-22. [PMID: 31559263 DOI: 10.1159/000501004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
335 Dubinsky MC, Magro F, Steinwurz F, Hudesman DP, Kinnucan JA, Ungaro RC, Neurath MF, Kulisek N, Paulissen J, Su C, Ponce de Leon D, Regueiro M. Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis 2022:izac061. [PMID: 35380664 DOI: 10.1093/ibd/izac061] [Reference Citation Analysis]
336 Daoud ND, Hashash JG, Picco MF, Farraye FA. Fecal Calprotectin from Ileostomy Output is Sensitive and Specific for the Prediction of Small Bowel Inflammation in Patients with Crohn's Disease. J Crohns Colitis 2021:jjab182. [PMID: 34633435 DOI: 10.1093/ecco-jcc/jjab182] [Reference Citation Analysis]
337 Rana MN, Lu J, Xue E, Ruan J, Liu Y, Zhang L, Dhar R, Li Y, Hu Z, Zhou J, Ma W, Tang H. PDE9 Inhibitor PF-04447943 Attenuates DSS-Induced Colitis by Suppressing Oxidative Stress, Inflammation, and Regulating T-Cell Polarization. Front Pharmacol 2021;12:643215. [PMID: 33967779 DOI: 10.3389/fphar.2021.643215] [Reference Citation Analysis]
338 Lam AY, Gutin LS, Nguyen Y, Velayos FS. Management of Recurrent Clostridioides Infection: A Difficile Problem in Inflammatory Bowel Disease Patients. Dig Dis Sci 2020;65:3111-5. [PMID: 32749638 DOI: 10.1007/s10620-020-06521-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
339 Shimizu H, Fujii T, Kinoshita K, Kawamoto A, Hibiya S, Takenaka K, Saito E, Nagahori M, Ohtsuka K, Watanabe M, Okamoto R. Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus. BMC Gastroenterol 2021;21:494. [PMID: 34949172 DOI: 10.1186/s12876-021-02043-6] [Reference Citation Analysis]
340 Balram B, Joshi H, Wong K, Kroeker KI, Dieleman LA, Halloran BP, Baumgart DC, Peerani F. Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial. Dig Dis Sci 2021;66:3985-92. [PMID: 33184796 DOI: 10.1007/s10620-020-06704-6] [Reference Citation Analysis]
341 Furihata K, Ishiguro Y, Yoshimura N, Ito H, Katsushima S, Kaneko E, Shimabe M, Mukai M, Watanabe R, Morishige T. A Phase 1 Study of KHK4083: A Single-Blind, Randomized, Placebo-Controlled Single-Ascending-Dose Study in Healthy Adults and an Open-Label Multiple-Dose Study in Patients With Ulcerative Colitis. Clin Pharmacol Drug Dev 2021;10:870-83. [PMID: 33512065 DOI: 10.1002/cpdd.918] [Reference Citation Analysis]
342 Colman RJ, Dhaliwal J, Rosen MJ. Predicting Therapeutic Response in Pediatric Ulcerative Colitis-A Journey Towards Precision Medicine. Front Pediatr 2021;9:634739. [PMID: 33681110 DOI: 10.3389/fped.2021.634739] [Reference Citation Analysis]
343 Varyani F, Argyriou K, Phillips F, Tsakiridou E, Moran GW. Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data. Drug Des Devel Ther 2019;13:4091-105. [PMID: 31819376 DOI: 10.2147/DDDT.S182891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
344 Kanters A, Liska D. The Impact of Ulcerative Colitis on Colorectal Cancer Prognosis: The Jury is Still Out. Ann Surg Oncol 2022. [PMID: 35015182 DOI: 10.1245/s10434-021-11307-0] [Reference Citation Analysis]
345 Sarbagili-Shabat C, Weiner D, Wardi J, Abramas L, Yaakov M, Levine A. Moderate-to-severe Endoscopic Inflammation is Frequent After Clinical Remission in Pediatric Ulcerative Colitis. J Pediatr Gastroenterol Nutr 2021;72:569-73. [PMID: 33346576 DOI: 10.1097/MPG.0000000000003018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
346 Huguet JM, Ferrer-Barceló L, Suárez P, Sanchez E, Prieto JD, Garcia V, Sempere J. Colorectal cancer screening and surveillance in patients with inflammatory bowel disease in 2021. World J Gastroenterol 2022; 28(5): 502-516 [DOI: 10.3748/wjg.v28.i5.502] [Reference Citation Analysis]
347 Zhou J, Liu J, Gao Y, Shen L, Li S, Chen S. miRNA-Based Potential Biomarkers and New Molecular Insights in Ulcerative Colitis. Front Pharmacol 2021;12:707776. [PMID: 34305614 DOI: 10.3389/fphar.2021.707776] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
348 Siddiqui MT, Cresci GAM. The Immunomodulatory Functions of Butyrate. J Inflamm Res 2021;14:6025-41. [PMID: 34819742 DOI: 10.2147/JIR.S300989] [Reference Citation Analysis]
349 Lightner AL, Vogler SA, Vaidya PS, McMichael JP, Jia X, Regueiro M, Steele SR. The Fate of Unifocal Versus Multifocal Low-Grade Dysplasia at the Time of Colonoscopy in Patients With IBD. Dis Colon Rectum 2021;64:1364-73. [PMID: 34623348 DOI: 10.1097/DCR.0000000000002063] [Reference Citation Analysis]
350 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
351 Abraham B, Glassner K. Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis. Curr Opin Gastroenterol 2021;37:344-50. [PMID: 33731642 DOI: 10.1097/MOG.0000000000000738] [Reference Citation Analysis]
352 Zhang B, Gulati A, Alipour O, Shao L. Relapse From Deep Remission After Therapeutic De-escalation in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis 2020;14:1413-23. [PMID: 32335670 DOI: 10.1093/ecco-jcc/jjaa087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
353 Lightner AL, Fleshner PR. Perioperative management of biologic agents in ulcerative colitis. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100866] [Reference Citation Analysis]
354 Noguchi T, Ando T, Emoto S, Nozawa H, Kawai K, Sasaki K, Murono K, Kishikawa J, Ishi H, Yokoyama Y, Abe S, Nagai Y, Anzai H, Sonoda H, Hata K, Sasaki T, Ishihara S. Artificial Intelligence Program to Predict p53 Mutations in Ulcerative Colitis–Associated Cancer or Dysplasia. Inflammatory Bowel Diseases 2022. [DOI: 10.1093/ibd/izab350] [Reference Citation Analysis]
355 Haasnoot ML, Mookhoek A, Duijvestein M, D'Haens GRAM, Bredenoord AJ. Prognostic Value of Colonic Tissue and Blood Eosinophils in Ulcerative Colitis. Inflamm Bowel Dis 2022:izac044. [PMID: 35275200 DOI: 10.1093/ibd/izac044] [Reference Citation Analysis]
356 Narula N, Wong ECL, Marshall JK, Colombel JF, Dulai PS, Reinisch W. Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00820-X. [PMID: 34329776 DOI: 10.1016/j.cgh.2021.07.038] [Reference Citation Analysis]
357 Dignass AU, Paridaens K, Al Awadhi S, Begun J, Cheon JH, Fullarton JR, Louis E, Magro F, Marquez JR, Moschen AR, Narula N, Rydzewska G, Travis SPL. Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scand J Gastroenterol 2021;:1-8. [PMID: 34932423 DOI: 10.1080/00365521.2021.2015801] [Reference Citation Analysis]
358 Dong X, Luo J, Lan P, Guo X, Zhao X, Wang X, Zhou F, Wang Q, Yuan H, Sun J. Magnetic resonance colonography with intestine-absorbable nanoparticle contrast agents in evaluation of colorectal inflammation. Eur Radiol 2021;31:4615-24. [PMID: 33409796 DOI: 10.1007/s00330-020-07609-8] [Reference Citation Analysis]
359 Takatsu N, Hisabe T, Higashi D, Ueki T, Matsui T. Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy. Core Evid 2020;15:7-20. [PMID: 32280316 DOI: 10.2147/CE.S179053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
360 Moutinho BD, de Barros JR, Baima JP, Saad-Hossne R, Sassaki LY. Immunosuppression and Malignant Neoplasms: Risk-Benefit Assessment in Patients with Inflammatory Bowel Disease. Am J Case Rep 2020;21:e920949. [PMID: 32218413 DOI: 10.12659/AJCR.920949] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
361 Gatenby G, Glyn T, Pearson J, Gearry R, Eglinton T. The long-term incidence of dysplasia and colorectal cancer in a Crohn's colitis population-based cohort. Colorectal Dis 2021. [PMID: 34041848 DOI: 10.1111/codi.15756] [Reference Citation Analysis]
362 Garrido I, Lopes S, Macedo G. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab037. [PMID: 33742651 DOI: 10.1093/ibd/izab037] [Reference Citation Analysis]
363 Dwadasi S, Zafer M, Goens D, Paknikar R, Dalal S, Cohen RD, Pekow J, Rubin DT, Sakuraba A, Micic D. Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. Inflamm Bowel Dis 2020:izaa326. [PMID: 33319248 DOI: 10.1093/ibd/izaa326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
364 Wei S, Sollano J, Hui YT, Yu W, Santos Estrella PV, Llamado LJQ, Koram N. Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia. Expert Review of Gastroenterology & Hepatology 2021;15:275-89. [DOI: 10.1080/17474124.2021.1840976] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
365 Dubois E, Moens A, Geelen R, Sabino J, Ferrante M, Vermeire S. Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort. United European Gastroenterol J 2020;8:933-41. [PMID: 32631177 DOI: 10.1177/2050640620941345] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
366 Cui DJ, Chen C, Yuan WQ, Yang YH, Han L. Integrative analysis of ferroptosis-related genes in ulcerative colitis. J Int Med Res 2021;49:3000605211042975. [PMID: 34510961 DOI: 10.1177/03000605211042975] [Reference Citation Analysis]